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1. Introduction 
1.1. Historical way – To go or not to go? 
Hyperthermia means the overheating of the living object completely (systemic) or partly 
(regionally or locally). If overheating can be identical with higher temperature then a/the 
question arises:  could overheating be identical with higher temperature or could “higher 
temperature” be caused only by “overheating”?  
Hyperthermia is one of the most common therapies in “house” applications. It is applied 
according to unwritten traditions in every culture and in every household. It can be applied 
simply to prevent the common cold but it is also good for its treatment moreover it is effective 
against various pains (joints, muscle-spasms, etc.), it can be applied for better overall 
conditions and simply for relaxation, or sometimes for spiritual reasons. The various heat 
therapies are commonly used complementary with natural drugs (teas, herbs, oils, aromas, 
etc.) or with natural radiations (sunshine, red-hot iron radiation, etc.) This popular medicine is 
sometimes connected with ritual, cultural and social events (ritual hot bath cultures), or 
ancient healing methods (like special spa treatments, hot-spring natural drinks, etc.).  
Hyperthermia has two certainly different fields in medicine: hyperthermia as a treatable 
disease or as a therapeutic method for various diseases (see Figure 1.) 
The source of whole body temperature increase as a disease can be internal, having fever by 
reaction to infections [1] or pyrogens [2] or malignant hyperthermia [3] as well. These 
whole-body “heating” processes differ also in their systemic reaction. The natural fever is 
induced by the living system [4], while the system works against the compulsory metabolic 
heating and tries to keep the temperature normal. Whole-body hyperthermia can be 
induced by external heating as well [5]. This happens in hot environments when the body is 
not able to cool itself down, although the system fights against the increase of its 
 
Hyperthermia 2 
temperature. This whole-body heating can be unwanted, mainly accidental from 
environmental sources, and it might be accelerated by additional heavy muscular work or 
by extra metabolic activity. This is a life-threatening situation with the danger of a heat-
stroke [6]. Hyperthermia requests definite and effective medical treatment when it appears 
as a disease, having elevated body temperature and the patient suffers from its serious 
consequences. This medical intervention applies therapies to reestablish the normal 
temperature of the body keeping the healthy homeostasis (overall stability) and handling 
the consequences of the unwanted high body temperature. 
 
Figure 1. Main categories of hyperthermia 
The popular heat-treatment applications are types of “kitchen medicine”: the old recipes are 
“sure”, the patient follows them, and is cured when everything is done according to the 
auricular traditional regulations. The meaning of “kitchen medicine” is: do it like in the 
kitchen, reading the process from the cookery-book: “heat it on the prescribed temperature 
for the prescribed time and the success is guaranteed”. This type of thinking has its origin in 
the ancient cultures, when the Sun - the fire, the heat - was somehow in the centre of the 
religious beliefs and philosophical focus.  
This idea of “take it for sure” is the disadvantage of the popular wisdom. It interprets this 
heating method as a simple causal process, “do it, get it”, however, hyperthermia is not as 
simple as traditions interpret it.  
1.2. Medical history of hyperthermia in oncology 
Hyperthermia is really an ancient tradition of human medicine. It is one of the very first 
known medical therapies, more than 5000 years old, [7].It has been historically recognized 
that malignant and infectious diseases can be successfully treated by raising the body 
temperature. 
It has been historically recognized that malignant and infectious diseases can be successfully 
treated by raising the body temperature. The first known oncotherapy by heat was made by 
an Egyptian priest/physician, Imhotep, in the 5th century BC. He exposed the tumors to 
“natural heat” (fever) before surgically removing them, which was in fact the very first 
immune approach as well.  
Hyperthermia
Disease 
caused by various 
functional irregularities or by 
accidental whole-body heating
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Many ancient cultures used heat to treat diseases and to maintain health. The thermal baths 
for their curative properties were used by the Greeks, the pre-Christian Jews and the 
Romans too [8]. The Chinese treated many diseases including syphilis and leprosy by hot 
spring baths [9]. Taking regular, extremely hot baths from infancy is the block of developing 
rheumy, according to the ancient Japanese medical notes. 
Naturally, this treatment had a sacral meaning in historic times, regarding the Sunlight, the 
fire and the heat as parts of the leading spiritual object in all ancient religions. This belief 
was behind when the heat was applied to locally affected parts of the body and to its 
entirety by means of hot water, steam, hot sand and hot mud baths. Natural hot air caverns 
connected with volcanic sources were also used. By the development of the medical 
knowledge, more and more heat applications were applied in practice. Later Hippocrates 
documented it [10], and he was convinced of its overall efficacy, telling when hyperthermia 
(fire) does not help, then the disease has to be declared as incurable. Hippocrates said: “Give 
me the power to produce fever and I will cure all diseases”. His followers in line were 
Aurelius Cornelius Celsus and Rufus of Ephesus, who believed in the curative effect of 
fever. The progress continued in the Middle Ages [11], when the ablation techniques (burn 
out the tumor) and hot-bathes dominated the hyperthermia practices, while the temperature 
measurement was worked out step by step.  
 The first clinical thermometer was introduced only later by Sir Clifford Allbutt in 1868. 
This was the start of the modern history of heat-therapies. The controllable era of 
hyperthermia was started. The temperature measurement made it possible to control 
the homogeneous heating and to make correlations with various physiological changes, 
like:  
 Increased rate of nerve conduction,  
 Elevation of pain threshold, altering muscle strength,  
 Possible changes in enzyme reactions, 
 Increased soft tissue extensibility,  
 Increased  heat- and field-stress reactions (mainly the developments of heat-shock-
proteins), 
 Increased venous and lymphatic flow, 
 Changes in physical properties of tissues, 
 Increased tissue extensibility, 
 Supporting muscular relaxation, reduced muscle spasm, 
 Lymphedema reduction, 
 Superficial wound healing, 
 Treatment of venous ulcers, 
 Assistance in removal of cellular debris and toxins, 
 Alteration of diffusion rate across the cell membrane, 
 Increased intramuscular metabolism, 
 Relieving pain, analgesia, 
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 Increased metabolic rate of contracted joints using heat and stretch techniques, 
 Need of stretching  during and/or immediately following the treatment, 
 Alterations of collagen properties, allowing it to elongate, 
 Increased rate of phagocytosis, 
 Increased ATP activity (assisting wound regeneration), 
 Psycho-feedback (pleasant sensing) [positive placebo effect], 
 Ability to control the chronic infection by increasing the circulation, 
 Heat increases the extensibility of fibrous tissues such as tendons, joint capsules and 
scars. 
It was applied for many various diseases like:  
 rheumy, 
 gout, 
 pain-management, 
 arthritis, 
 some dermatological disorders, 
 muscle spasms, 
 supportive therapies in sport, 
 some gynecological disorders, 
 some allergies, 
 rhinitis, common cold, 
 pediatric ear diseases, 
 wound healing,  
 supporting the general rehabilitation process. 
A Nobel Prize was also granted for hyperthermia in Physiology & Medicine in 1927 "for his 
discovery of the therapeutic value of malaria inoculation in the treatment of dementia 
paralytica" to Julius Wagner-Jauregg, (1857-1940, Austria). 
The application of heat in oncology has been restarted with huge intensity. Among the first 
modern curative applications in oncology, Busch [12] and Coley [13] were successful at the 
end of the 19th century with artificial fever generated by infection and toxins, respectively. 
These systemic applications were soon followed by local and regional heating by 
Westermark F. [14], Westermark N. [15], and Overgaard K. [16]. The leading German 
surgeon at that time, Bauer KH’s opinion in his monograph “Das Krebsproblem” about the 
oncologic hyperthermia is typical: “All of these methods impress the patient very much; 
they do not impress their cancer at all.” However, very early, in 1912, a controlled Phase II 
clinical study was published, 100 patients showing the benefit of the thermo-radiation 
therapy [17]. Tremendous number of publications were prepared in the first quarter of the 
20th century, expecting fantastic development in the topic, [18], [19], [20], [21], [22], [23], [24], 
[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], 
[44], [45], [46], [47], [48], [49].  
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1.3. Heating methods – local and systemic 
As it was shown before, there are two, basically different hyperthermia processes: the 
systemic (heats the complete body, whole-body treatment), and the local/regional heating 
(heats only a part of the organism). The two basic kinds of the heating methods also differ in 
their physiological limitations: the systemic treatment, of course, modifies the entire 
physiology of the organism, and that could limit the applied energy-absorption and body-
temperature. There is a possibility to absorb energy in large volume equally or having a 
layer-by-layer changing front (heat-diffusion, heat-flow flux) depending on the penetration 
depth of the actually applied energy. Nevertheless, the old direct heating methods (hot 
solids or liquids in the area or in the nearest body cavity) were not effective enough for local 
deep heating without skin injury.  
Thermodynamically the systemic and local/regional treatments differ by their energy-intake. 
The whole body treatment is based on the blood-heating (mostly heats up the subcutaneous 
capillary bed, or heats the mainstream of the blood directly with extracorporeal heater), 
while the local hyperthermia is definitely a tissue heating approach. This difference 
drastically divides the two methods from thermal point of view. In whole body treatment 
the blood is a heating media, it delivers the heat to the tumor and heats it up; while in local 
treatment, the blood remains on body temperature during the local heating, so it is a cooling 
media (heat-sink) for the locally heated tumor, (see Figure 3).  
 
Figure 2. Opposite thermodynamic mechanisms of whole-body, systemic (a) and local (b) heating 
methods. The blood-heated tumor in whole body treatment reaches thermal equilibrium after a certain 
time, while the local treatment is always in non-equilibrium state, because the body temperature is 
lower than the heated tissue, creating intensive heat-flow from the target to the neighborhood. 
The systemic (whole-body) treatment uses the blood-circulation to heat-up the body. (see 
Figure 3.) 
The artificially elevated body-temperature is the source of heating in fever inducing 
methods. Fever inducing can be solved with various drugs [50], as well as with special 
inflammation-inducing toxins.  
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The oldest whole body heating was the contact method, immersing the patient into the hot 
bath, but due to its numerous disadvantages of this method, it is rarely in use any more. 
Mainly two direct methods are available in the modern medicine to make systemic 
hyperthermia. The less frequently used is the extracorporeal (the blood is heated outside the 
body), or the intracorporeal (the blood is heated in-situ in the body). In most cases the 
capillary bed of the subcutane area is heated by conductive (e.g. hot-bath) or radiative (e.g. 
infrared) way, using extra-corporal blood-heating. This method takes out the blood from the 
continuous flow by a definite arterial outlet and the outside heated hot blood is pumped 
back to the patient.  
 
 
 
Figure 3. Categories of whole-body hyperthermia 
The whole-body heating could be solved in various ways, like steam, water or radiation 
heating (see Figure 4.). There are other possibilities as well (e.g. wax heating, hot-air heating, 
etc.) but the limited possible heat-flux and the poor technical realizations hinder these 
solutions. By all of these whole-body heating forms the patient’s safety has to be seriously 
considered. These are based on the blood-heating in the subcutaneous capillary bed, and the 
physiological reactions (vasodilatation and sweating) work well against the huge heat-flux 
into the body. The long heating time is also challenging (over an hour) moving the body 
away from the healthy homeostasis. The heat-flux through the skin is limited by the heat 
injuries (~1 W/cm2 is the limit) so the contact heating with steam and water has definite 
problems. The radiation heating can be solved by special infrared wave (Infrared A) which 
penetrates deeper (~1-2 mm) into the subcutaneous layer, and can manage higher energy-
flux without burn injuries. The method has many early descriptions [51], [52], [53], [54]; but 
the dominant systemic hyperthermia method is based on the infra-red radiation by multi-
reflecting filtering [55], [56] or by water-filtering [57], [58], [59], [60]. 
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Figure 4. Various main methods of the whole-body heating: (a) steam, (b) water, (c) electromagnetic 
radiation 
When the whole body is systemically heated, it has a strict physiological limit: 42 ºC in 
humans. The thermal distribution till this level is homogeneous and well controllable. No 
hot-spots exist, no question arises about the isotherms; the physiologically extreme 
temperature can be fixed all over the body. Suppressing the risk; a decreased treatment 
temperature (moderate WBH/whole-body fever-range thermal-therapy) is also applied. The 
application of lower temperatures for longer time period (fever-therapy, or mild-
hyperthermia) also showed surprisingly good efficacy for whole-body hyperthermia 
treatments [61], [62], [63], [64]. The whole body hyperthermia and even its fever-range 
versions mean effective immune support, [65], [66], [67], [68], which might be a very 
important factor for patients with weak immune-system.  
The local/regional hyperthermia has also large categories (see Figure 5.) and various 
technical choices (see Figure 6.). The widely applied technical solutions were available only 
after the discovery of the electromagnetic heating. The electromagnetic waves can penetrate 
deeply into the body. Dominantly, the local/regional systems work by radiative [69], [70], 
[71], or by capacitive [72], [73], [74] technical solutions.  
Both heating categories form large groups of treating options having special subcategories, 
which are involved in different physiological actions and support different reaction 
mechanisms in the organism.  
Technically, a huge variety of heating can be applied by heat therapies. Its energy-
production, its selectivity, locality, kind of energy-delivery, invasivity control, frequency of 
the electromagnetic waves, as well as their medical applications and combination with other 
methods make the heat-therapies different, (see Figure 7.).  
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Figure 5. Categories of local heat-treatments 
 
Figure 6. Main technical solutions of local heating: (a) contact heat, (b) deep-heating, (c) radiative 
heating, (d) immersing a part of the body in hot water 
These combinations involve more than a hundred solutions of hyperthermia used as 
treatment, which make the therapy indefinite in its applications. This emphasizes the reason 
why the present review tries to summarize the main categories.  
The thermodynamic situation, and in consequence of the physiological effects of the 
systemic and local/regional heating modalities are entirely different. There is a definite 
difference between the temperature of the blood and the inter-capillary volume in the 
microscopic structure of the target: the blood-arteries are hot-sources in case of systemic 
treatment, they deliver the heat. However, in case of local/regional hyperthermia it is 
entirely the opposite: the blood is relatively cold (remaining on unchanged body 
temperature), the arteries are heat-sinks which are cooling the tumor down, in fact, these 
work against the local heating.  
One question automatically arises: when the heat, the energy-flow has a central role in 
hyperthermia, then what does the temperature do in the living systems? 
The temperature as the average of kinetic energy in the system has a double role in the control 
of the heat-absorption. It characterizes the heat-absorption, when the heating is homogeneous, 
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and its gradients (non-homogeneities) are the driving forces of the dynamic processes in case 
of microscopic (non-homogeneous) heating. The average temperature does not inform us 
about the distribution of the real energy-absorption (see Figure 8.).  
 
Figure 7. Categories of the possible hyperthermia methods. A few hundred of healing processes have 
been introduced 
 
Figure 8. The average temperature cannot characterize the thermodynamic situation. The internal 
temperature differences can serve as driving forces of various processes on the same average 
temperature of the system 
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Herewith we do not discuss the extreme temperature facilities in local treatments, the 
ablative techniques with high temperature (heat-ablation, [75]) or low-temperature (cryo-
ablation, [76]).  
1.4. Technical history of local hyperthermia in oncology 
Despite the hyperthermia was among the very first medical treatments in human medicine, 
this approach has ambivalent evaluation as a therapy. While it is popular in households to 
“treat” many diseases like common cold, pain, various orthopedic problems, etc., it is on the 
periphery of the serious medical therapies. This frustration characterizes the complete 
history of hyperthermia in medicine, and explains why hyperthermia has no well- deserved 
place in the medical armory to treat various diseases.  
At the end of the 19th century, energy delivery by electromagnetic fields became possible; 
but the real technical revolution of the heat therapies was when the modern microwave 
heating was developed, and applied in medicine from the middle of the 20th century. This 
focused, temperature-based deep heating became one of the line (focused local/regional 
heating), while the other was the whole body heating with various methods. In local 
heating, the paradigm is to reach the appropriate temperature locally.  
Nevertheless, the intensive use of hyperthermia in oncology began in the last third of the 
20th century. The first symposium on oncological hyperthermia was held in Washington DC, 
USA in 1975; and the second one in Essen, Germany in 1977. Both conferences were 
supported by the local scientific communities. We may consider the birth of the modern 
oncological hyperthermia from this time on, and take it as a strong candidate and a member 
of the acknowledged tumor therapies.  
The original idea of the hyperthermia was the “fire by fire” concept: set a controlled contra-
fire depleting the possible fire-supply, blocking the coming large bush-fire endangering a 
house. The heated tumor is forced to higher metabolism; high metabolic rate of the cancer 
lesion is gained by elevated temperature. However, when the surrounding is intact, it 
delivers the same amount of nutrients as before, it does not deliver more glucose for the 
forced metabolism Figure 9. The tumor very quickly deflates from nutrients, empties all its 
energies, suffers and burns away. 
 
Figure 9. The focused local heating situation, expecting the locality for longer time 
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Indeed, there are many factors showing the validity of this assumption, but the 
breakthrough to accept the method widely hasn’t been reached in the long historic period. 
The appropriate temperature selectively administered in the tumor still cannot be reached. 
This fact forms a lot of questions in the published literature:  
 Is the community of radiation oncologist ready for clinical hyperthermia? [77]; 
 What happened to hyperthermia and what is its current status in cancer treatment? [78]; 
 Where there’s smoke, is there fire? [79]; 
 Should interstitial thermometry be used for deep hyperthermia? [80]; 
 If we can’t define the quality, can we assure it? [81]; 
 Is there a future for hyperthermia in cancer treatment? [82];  
 What is against the acceptance of hyperthermia? [83]; 
 Progress in hyperthermia? [84]; 
 Prostate cancer: hot, but hot enough? [85]; 
 Is heating the patient a promising approach? [86];  
 Hyperthermia: has its time come? [87]. 
Many of the researchers evaluating the capabilities of oncological hyperthermia share the 
opinion expressed in the editorial comment of the European Journal of Cancer in 2001: the 
biological effects are impressive, but physically the heat delivery is problematic. The hectic 
results are repulsive for the medical community. The opinion, to blame the “physics” 
(means technical insufficiency) for inadequate treatments is general in the field of 
oncological hyperthermia, formulated the following statement: “The biology is with us, the 
physics are against us [82]. In the latest oncological hyperthermia consensus meeting the 
physics was less problematic. However, in accordance with the many complex physiological 
effects, a modification was proposed: “The biology and the physics are with us, but the 
physiology is against us” [88].  
The most problematic issues have always been technical: how to heat in depth, locally 
focused, being selective for malignant cells, and the other side: how to control it and how to 
measure the efficacy of the treatment? Even when the local treatment is focused well, the 
temperature by its way tends to be equalized; the focus is extended by time, due to the very 
effective heat-exchanger – the blood-stream. The heated tumor strongly exchanges its heat 
with its healthy surrounding, extending the focus gradually and increasing the local blood-
flow. This unwanted effect has some problematic consequences:  
1. The heating focus is growing, it is not correct any more, so the healthy tissue is also 
heated up,  
2. The distributed spots of the tumour (local metastases) can be covered only by on 
average, covering the area completely with the intermediate healthy parts,  
3. The natural movements of the patients (i.e. due to the breathing) cannot be followed by 
the focus,  
4. The blood-flow is increased locally, supplying the tumor with nutrients (first of all with 
glucose) and the higher temperature gains the local metabolic rate as well,  
5. The intensive tumor-metabolism produces high level of lactic acid in the volume, which 
lowers the pH and forces the blood to buffer it. The blood starts to shift to alkaline and 
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the alkaline blood delivers more oxygen to the volume, by positive feedback 
mechanism,  
6. The intensive blood-flow has a risk of the further disseminations and metastases, 
7. The heat flow to the surroundings can damage the healthy neighbourhood, 
8. Enlarging  the sphere having certain temperature gradients increases the area of the 
injury current which supports the cell-proliferation, 
9. The growing heated volume is uncontrolled, the vigilance of the process becomes 
complicated,  
10. The incident energy might burn the skin, so surface cooling is necessary. The heat-sink 
of the surface decreases the incident power, but its quantity has no measurable 
parameters. This is the reason why only the temperature in the target will  orientate the 
control of the treatment process,  
11. The necessary temperature measurement is mostly invasive, which could cause many 
complications, including inflammation, bleeding, infection, dissemination of the cells, etc.  
12. The microwave heating might do harm not only by its unwanted hot-spots, but also 
with its ability to create carcinogens in situ. 
These technical challenges are definitely complex, and can make the actual hyperthermia 
treatment uncontrolled. This branch of problems could be the reason for some controversial 
results and the weak acceptance of the conventional hyperthermia among medical experts.  
2. Malignant diseases – To heat or not to heat? 
The popular terms “heat-dose”, “temperature-gain”, “thermal dose”, “energy-intake”, “energy-dose” 
may have different definitions in various individuals who use them. Our first task is to clarify 
the differences between these (in popular literature many times used as synonyms) terms.  
Nevertheless, the temperature is not heat, not even energy. Temperature, in this sense, is a 
hypothetical value of the average energy. Particles have various energies and it could happen 
no any individual particle has such definite energy as the average (the temperature) 
indicates.The temperature is an average; we can define it only on a large number of 
participating units (particles). The average energy of the various particles at normal human 
body temperature (ideal thermodynamic model) is ~ 2.5 kJ/mol. This relatively large energy 
is embedded and blocked in the actual system. (It is so large, that if it could be liberated 
within one second, the obtained power would be 2.5 kW/mol.) This average thermal energy 
limits the internal bonds and interactions, because any lower energy bond will be destroyed 
by this thermal background. This internal energy could make abrupt changes by such 
chemical reactions, by which activation energy is smaller (or equal) than the actual thermal 
average energy. The weakest bonds in life are the hydrogen-bridges, having 18 kJ/mol in ice 
[89] and ranging 3-30 kJ/mol in various compounds in living objects [90].  
Pumping heat into a system can increase its temperature. The result of heating is not a 
definite temperature. The resulting temperature always greatly depends on how the heat is 
consumed in the system, and how the system transfers this energy to its environment. 
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Pumping the same energy into identical volumes, but having different surfaces, the 
temperature increase will be definitely different, because the volume is differently cooled 
down by the environmental conditions. Furthermore, the heat can make structural or other 
rearrangement in the material, it could be transformed into work without temperature 
increase of the system. For example: melting the ice absorbs energy without temperature 
increase, still it is completely transformed into liquid. The heat, which is pumped in to the 
system at this phase transition does not increase the temperature; its energy is used 
completely to change the structure of the material from solid to liquid. 
Other clear example is the Sun radiation to the Earth. A huge part of the energy of the Sun’s 
radiation is converted to the meteorology (like wind or rain), their mechanical effects (like 
waves in the ocean, like distortion of the rocks). The Sun’s energy is the solely energy-source 
of the life processes, and this energy of the Sun makes our oil reserves, allowing us to use 
this energy for various applications in our everyday life. So the simple electromagnetic 
radiation (the spectrum of the Sun) is converted to the various kinds of energies in the Earth. 
Only a fraction of the radiation is realized as heat and rising temperature.  
Other simple example is the human energy-intake: a female adult eats ~1600 kcal/day. When 
she takes more energy a day, it will not change her body temperature at all. However, when 
she gets this energy from radiation, she will starve, despite of the fact that she gets more 
energy than she could take from nutrients.  
When there are so serious differences between the heat and temperature, why do we 
confuse them? The main reason is: we fix our attention to simple situations when we heat 
such materials which distribute the energy immediately all over the system, making thermal 
equilibrium without internal work (reactions, dilatation, etc.) in the system. In such cases, of 
course, all the heat energy increases the internal energy of the system, and so it is 
distributed in it, and proportionally increases its temperature.  
When we fix our attention to such systems, like heating water in its liquid form, the applied 
heat and temperature are strictly proportional in a certain interval (when the water is 
definitely liquid). However, we have a problem even in this simple system. When a phase-
transition occurs, we lose this proportionality completely. At the/a study of hyperthermia in 
living systems, we have to well distinguish the overall energy, the heat energy and the 
temperature (which is not energy) from each other. 
“The use of thermodynamics in biology has a long history rich in confusion.” [91]. The main 
complication is the fact that life cannot be studied isolated from its environment, and so the 
energetically open system could lead to numerous uncertainties, leading sometimes to 
mystification as well.  
2.1. The heating paradigm 
The idea of the local heating effect to burn-out the energy sources of the malignancy has 
dominated the hyperthermia applications from the time of Hippocrates. Its operation 
measured by modern methods [92], shows definite decrease of ATP and increase of lactic 
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acid in tumors after hyperthermia treatment. The ATP depletion makes a heavy ionic-
imbalance in cells [93]. Furthermore, the increased temperature can slow down or even 
arrest DNA replication, [94], [95].  
Higher tissue temperature stimulates the immune system [94] with observed increase in 
natural killer cell activity [96]. Moreover, the elevated temperature distributes tumor-
specific antigens on the surface of various tumor cells [97] and assists in their secretion into 
the extracellular fluid [98], triggering the immune reactions against the malignant cell [94]. 
Hyperthermia has shown significant pain-reduction during treatments [99]. This makes this 
method excellent to improve the quality of the patient’s life and it can be applied as 
palliative treatment when the curative solution does not work.  
Multiple effects can be counted by homogeneous heating the living organisms completely or 
locally. One of the decisional factors is the vasodilatation. The induced vasodilation 
increases:  
 Blood flow 
 Capillary filtration 
 Capillary pressure 
 Oxygen perfusion 
These induce the following actions:  
 Increases fibroblastic activity and capillary growth, 
 Increases the oxygenation in the volume, 
 Increases drug-delivery in the volume, when the drug is administered systemically,  
 Increases the nutrition concentration in the volume,  
 Increases the metabolic activity in the volume (higher quantity of nutrition, oxygen and 
higher local temperature), 
 Increases the field-dependent effects, (membrane excitation, activation of signal 
pathways, etc.),  
 Increases the effects on the blood-structure in the volume,  
 Increases the micro vascular perfusion (circulation), nutrients, and phagocytes. 
The chemo-drugs are delivered to the tumor by the blood-stream. Higher local temperature 
increases the microcirculation in the heated volume, [100], [101], [102], [103], [104], [105], 
[106], [107], [108], [109]; and with this it enhances the efficacy of the conventional chemo-
therapies [110]. The synergy between heat-treatment and many of the chemotherapies is 
well-established [111], [112].  
Further support is that the hot drug is more reactive [113], providing excellent possibility to 
synergy, which is even more effective when we consider the accelerated drug metabolism 
and gained pharmacokinetic parameters. The thermo-chemotherapy results in a better 
therapeutic effect and it increases the target specificity as well as it reduces the systemic side 
effects [114], [115]. In some cases the low-dose chemotherapy could be used [116], [117] with 
the hyperthermia promotion, it is also applied in low-dose metronomic chemo-regulation, 
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[118]. Furthermore, hyperthermia acts in G0 phase of cell-division which makes the action of 
conventional therapies possible on these cells too.  
For radiotherapies, the increased microcirculation sensitizes the effect of ionizing radiation 
[119]. The primarily applied heat can enhance the effect of ionizing radiation because of the 
higher oxygen concentration in the area. Furthermore, the most efficient action of 
hyperthermia is in S-phase [120], which well completes the weak effect of radiotherapy in 
this phase of the cell-cycle. The heat-induced decrease of the DNA-dependent protein-
kinase (DNA-PK), [121] is also a radio-sensitizer. Sensitizing the classical ionizing-radiation 
by hyperthermia has been well-known [122], [123] for a long time, and different review 
articles have summarized this knowledge [124], [125], [126], [127]. The advantage of 
combining heat-treatment with the classical ionizing-radiation is unambiguous, [128], [129], 
[84], the synergy between the methods is well known [130], [122] and successfully applied 
[131], [132], [106].  
Hyperthermia has also been found to have pronounced advantages for surgical 
interventions. Through hyperthermia induced inhibition of angiogenesis and heat 
entrapment, the outline of the tumor often becomes pronounced and the size of the tumor 
often shrinks, making previously dangerous operations possible [133]. The feasibility of the 
preoperative application for locally advanced rectal cancer is well shown in a Phase II 
clinical trial [134]. Postoperative application of hyperthermia has also been thought to 
prevent relapses and metastatic processes [132]. Intraoperative radiofrequency ablation [135] 
and local hyperthermia [136] have also been used to improve surgical outcomes.  
The combination of hyperthermia with gene-therapy also looks very promising, as shown 
by the successful combination of hyperthermia with HSP-promoter mediated gene therapy 
in cases of patients with advanced breast cancer [137]. Hyperthermia improved the results 
of the HSP-promoter gene therapy by inducing local HSP production and by enhancing the 
local rate of release from liposome [138]; it was also helpful in the double suicide gene 
transfer into prostate carcinoma cells [139]. It was proven that this combination therapy was 
highly selective for mammary carcinoma cells. Also the heat-induced gene expression could 
be an excellent tool in the targeted cancer gene therapy [140].  
Combination with hormone therapies is also a vivid method, applied for prostate [141]; and 
in melanoma treatment [112]. Enzyme-therapy [142], photodynamic therapy [143], gene 
therapy [144], immune- [145] and other supportive-therapies [146] are used in combination 
with hyperthermia.  
 All these factors position hyperthermia to one of the most effective treatments in 
oncology. Since these are mostly temperature dependent effects, an accelerated race has 
been started for the rising temperature and providing the highest available thermal 
support for the conventional therapies. Most of the applied electromagnetic techniques 
started to gain their power over 1 kW, providing powerful radiative, capacitive and 
magnetic effects to increase the temperature in depth in the targeted tissue.  
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2.2. Targeting complications  
The large heating energy heats up the healthy surrounding as well, see Figure 10. The 
blood-flow will be enhanced, the nutrients supply will be higher and the result is the 
opposite of our aim. The situation becomes even worse by continuing the high-energy 
heating: the high blood-flow helps the dissemination [147], [148], [149] and could gain the 
metastases: Figure 11. With this, we can definitely worsen the survival and the quality of life 
of the patient. This problem gained the official policy in many oncological departments: 
avoid application of hyperthermia in oncotherapies.  
 
Figure 10. The real situation heats up the surroundings, the local heating does not remain locally 
focused 
 
Figure 11. The large heated volume is not controlled from the focus, and makes the malignant 
dissemination possible by the high blood-flow in the healthy surroundings 
It is plausible: the temperature spreads to the neighboring volumes independently of how 
precise the focus of the energy is. The energy can be focused, but the temperature seek is to 
be equalized and the focused energy-intake will heat up the tissue out of the focus too. This 
process is very rapid anyway in such good heat-conduction material as the living tissue. The 
cooling becomes even more emphasized, considering the physiological feedback 
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mechanisms, which tries to reestablish the local homeostatic equilibrium by intensified 
blood-flow. The blood is on body temperature and this way it is an effective cooling media. 
This is the reason why huge energy is necessary to compensate the heat-loss of the tumor, 
and keeps the tumor temperature actually higher than its healthy environment.  
A typical capacitive coupling solution pumps enormous energy, [150]. The rise of 
temperature, applying 1200 W energy after 45 min, was 4.8 oC but the reached focus differs 
with about 1 oC only from its untargeted neighborhood. In case of radiative applications the 
situation is the same. The temperature elevation in the tumor after 57 min was 4.2 oC; 
reached by as high power as 1300 W [151]. The overall heating obviously shows unwanted 
hot-spots. The elapsed time smears the relatively focused temperature. The temperature 
increase in the tumor was 4.2 oC on average, while in the surrounding muscle it was only 3.8 
oC [151]. Is this the focus we expected? (Note, a standard speedy electric tea kettle uses 1300 
W to boil a cup of water within a couple of minutes. The increase of the temperature for the 
~ 0.3 liter water is ~75 ºC. We apply, in these cases, the same power reaching a temperature 
increase ~7 ºC during 60 minutes).  
Further problems occur by a huge surface energy-density pumping high energy dose in 
depth. Due to the huge thermal load on the skin, more and more sophisticated methods 
have been/are being developed to cool the skin and to avoid its burn. A new technical race 
started: cooling the surface together with the increase of the incident power.  
The maximal surface power density could be 1 W/cm2 (10 kW/m2), for ~ 42 min, (see Figure 
12. [152]), which is a definite limit of the energy intake.  
 
Figure 12. Threshold of surface blisters by power density through the dermal layers 
In general, the injury level (threshold of blisters) depends on the full integral of the heat-
flux, consequently, a longer treatment-time has lower power limit of use and for example, 
the 60 min treatment allows maximum 0.5 W/cm2 without surface toxicity. Cooling is 
applied in most of the technical solutions to avoid the surface burn from overheating, see 
Figure 13.  
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Figure 13. The incident power can overcome the threshold of blisters (a). Appropriate surface cooling is 
introduced to avoid this burn (b) 
The surface cooling has a double effect: it cools down the surface taking away the surface 
energy to avoid the burn and to keep the heat-sensors (which are located in the near-surface 
subcutaneous area) of the body in the pleasant range of feeling.  
However, the surface cooling creates serious problems too:  
It makes the control of the energy intake ambiguous, no precise dose can be measured by 
the forwarded power. When the forwarded dose is 100 W, the cooling is 50W and the 
intensive cooling of the blood circulation on the surface is 30W and then maximum 20W can 
be absorbed in the target (see Figure 14.).  
 
Figure 14. The forwarded power and the cooling power work oppositely. No idea about the real power 
pumped into the body 
The high energy loss in the surface area is mainly due to the adipose layers, which are good 
electric- and heat-isolators [153]. Their isolation ability depends on their thickness, and it is 
controlled by the blood perfusion. When we cool down the surface, the homeostatic control 
will increase the isolating layer (see Figure 15.) by reducing the blood-flow in the area. 
There is a misleading competition on the power, which is applied for local hyperthermia. 
The subcutane adipose tissue is an electric- and heat-flow blockade, and its conductivity 
decides the current transport at a fixed power transmission. The applied voltage depends on 
the contact area and on the applied frequency as well. The available devices for local heating 
range from 150W to 2000W and, in fact, the local temperature in the tumor ranges between 
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40-45 oC. The local maximal temperature in most cases depends more on the patient than on 
the incident power. At the end, the origin of the heat-flow will not exceed the 1 W/cm2 on 
average. The higher isolation will absorb more energy, and so we need more cooling for 
safety and so on, see Figure 16. It is a positive feedback regulation, requesting enormous 
energies.  
 
Figure 15. The blood-perfusion changes the conductivity and the relative permittivity as well 
 
Figure 16. The physiologically regulated optimum is necessary for energy control. The large cooling 
grows the physiological reaction, creates a layer of isolation, which accelerates the dangerous surface 
overheating by positive feedback 
Further complication in the control is the value of blood-flow, which is temperature 
dependent. The physiologic effects connected with the blood-flow are considered to be 
important and it is studied in details, [154], [155], [156], [157], [158].  
The cooling energy is indefinite. The applied definite heating is modified with this energy-
factor, making the really applied energy immeasurable. The hyperthermia dose must be the 
physically correct, accepted specific-energy absorption rate in J/kg, as we do it in the case of 
ionizing radiation too. The dosing in this case requests other, deep-inside measurement for 
indication of the process: the temperature as the character of the really absorbed energy. 
However, it is again problematic from a technical point of view: in fact, the absorbed energy 
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distribution and the gained temperature are very different [159]. The reason is simple: 
provide the same energy to identical volume but the blood-flow is different in every case so 
it will result in different temperature. The physiology modifies the temperature! It is not 
possible to match the specific absorption rate (SAR) and the developed temperature.  
The measurement of the power is missing, due to the fact that cooling is immeasurable and has 
a modifying effect on the temperature. This makes the temperature measurement in the target 
important, as this is the only parameter which gives us some idea about the absorbed energy, 
(see Figure 17.). This (generally invasive, measurement) makes it possible to have orienting 
value of the absorbed power in general, and sometimes it is important for safety to avoid the 
unwanted hot spots as well. For the successful energy dose control we have to know the 
energy taken away by the cooling. This underlines the importance of the control of the surface 
cooling triggered by the actual physiological conditions in the subcutaneous capillary bed.   
 
Figure 17. The control of both the energies together with the physiological parameters make 
oncothermia safe and effective 
The full unsuccessful temperature focusing together with the intensive cooling process in 
conventional hyperthermia is, borrowing the words from Shakespeare, “much ado about 
nothing”.  
Dr. Storm a recognised specialist of hyperthermia formulated [78] a general opinion: “The 
mistakes made by the hyperthermia community may serve as lessons, not to be repeated by 
investigators in other novel fields of cancer treatment.”  
2.3. What to learn from nano-scale energy-liberation? 
The general idea of microscopic heating is simple: the heating energy is not liberated in a 
sudden single step, but regulated and multiple small energy liberation does the same job, 
(see Figure 18). In our case, the forwarded energy selectively targets the most influential 
areas. Instead of the high, general energy pumping into the lesion, the energy is liberated at 
the membranes of the malignant cells.  
The microscopic effects, instead of the large energy liberation, is one of the most update 
thinking in energy source developments.  
The conventional engines in vehicles use the energy of explosion of different chemicals (e.g. 
petrol, diesel, kerosene). The explosion by a spark or heating over their activation energy 
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liberates large energy in a short time, and only a small fraction of this could be applied 
beneficially, most of the energy is radiated, conducted or lost in various other ways. One of 
the largest losses is the heat-exchange by the high temperature, which somehow has to be 
used again (e.g. intercooler, turbo). The latest solution, however, is the set of microscopic 
explosions, promoting the chemical reactions individually by a membrane control (i.e. fuel 
cell solution) and using the energy step-by-step as a sum of the micro-reactions. The 
relatively low efficacy combusting engines are intended to be replaced by the fuel-cell 
energy-sources combined with electric motors, which are based on the membrane regulated 
microscopic reactions of gases. (Mostly hydrogen and oxygen gases are in use.)  
In fact, life “invented” the controlled energy-liberation by micro-processes, blocking the 
sudden, explosion-like energy liberation, driving the processes small subsequent energy-
conversion steps instead. In the living objects the energy is liberated gradually in a “ladder” 
of multistep processes, and this is also moderated by surface reactions. 
 
Figure 18. The difference between macro- and micro-liberation of energy. The latter is much more 
efficient. 
The applied power and its efficacy are usually not connected. Good examples can be found 
in our everyday life, in systems like the standard light bulbs and the energy safe ones using 
a fraction of the power for the same light; or the various power-consumptions of cars, 
having equal performance, or the various fuel consumption of them having the same 
engine-power. The incandescent bulb creates light by high-temperature filament, which 
heats up the environment, having only 10% efficacy.  
Fluorescent technology solves this task more smartly: it makes the energy-liberation 
selective where the effect radiates light only (see Figure 19.). Fluorescent particles turn the 
UV from mercury excitation to visible light. The full process has approx. 45% efficacy.  
The LED technology is even more effective, because no intermediate mercury-plasma is 
used, direct annihilation of the electrons and electron-holes emit the light with over 90% 
efficacy! (see Figure 20.) 
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Figure 19. Fluorescent technology. The energy is liberated by micro-”explosions”, excited by an UV 
radiation of the mercury-plasma 
 
Figure 20. LED technology. The energy is liberated by micro-”explosions” by using the energy of the 
excited electrons 
This way, the more intensive light (virtually higher temperature micro-explosions) need less 
energy by the block of the wasted energy to heat up the environment instead of the visible 
light emission: the same light-emission needs 60W, 13 W and 5 W in cases of incandescent, 
fluorescent or LED light-sources.   
The present main-stream thinking of oncological hyperthermia is a typical loss of aims by 
illusions: the temperature only makes conditions that are implements and not the aim. The 
question “Tool or goal?” has become relevant to study the temperature alone. By a simple 
example of mixing the tool and the goal in our everyday life: the graduation is a tool for our 
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professional life, however, when somebody regards the certificate of studies as a goal, its 
application, the aim of the study is lost.  
Mixing the tool with the action creates false goal in hyperthermia application: increase the 
temperature alone. This “auto-suggestion” creates such a situation when magnetic resonant 
imaging (MRI) is applied to control the temperature during the treatment, instead of using 
this capable imaginary method to see what is happening in the tumor indeed.  
3. Bioelectromagnetic selection – To select or not to select? 
In hyperthermia applications the macroscopic heating centers on the equal (homogeneous) 
temperature of the entire targeted volume, irrespective of its content and the ratio of the 
tumor-cells in the target, (see Figure 21./a.). However, the target volume has only a small 
fraction of active malignant cells, and the heating process would be enough for those alone, 
avoiding heating (and wasting energy) to the other part of the target-volume. The micro-
heating concept works differently, and heats the selected malignant cells only absorbing the 
energy non-equally in the target (see Figure 21/b.).  
 
Figure 21. The schematics of macroscopic and microscopic heating of tumor 
In this case, the lost energy is minimal; the efficacy of the energy utilization and its control is 
maximal. The energy is concentrated in this case directly to the chemical reactions and does 
not involve the above listed losses. The energy liberated by the micro reactions is  used for 
the desired job in full, while the explosion-like, huge energy-supply in short time cannot be 
used optimally, due to the intensity of the immediate offer for the available energy is too 
much for prompt use. This causes a large demand of waste and a low efficacy of the desired 
effect. The problem of the heating, however, is that it shows a false, specious effect of 
applications in biology. When the liberated energy is not used as active biochemical or 
biophysical driving-force then the waste appears as a simple growth of the temperature in 
the target. This deceptive illusion seems to have higher efficacy. This, of course, heats 
everything in the target. The excess energy is wasted in the neighborhood of the malignancy 
and gaining the average energy of all the parts in the target, irrespective its malignancy or 
its electrolyte state. This is a typical wasting of energy, using it for the actually not-necessary 
energizing of healthy parts. This massive heating forces the homeostatic feedback 
mechanisms acting against the growth of drastic temperature growths.   
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The oncological hyperthermia application, which uses the nano-scale heating technology 
(called oncothermia, [160]); the radiofrequency (RF) current flows through the chosen 
volume of the body (see Figure 22.), heating up the cell-membrane individually (see Figure 
23.). The cell-membrane is a good isolator and so the current is most dense at the 
extracellular electrolyte in the immediate vicinity of the cells. Of course, when the absorbed 
energy is too much, the individual cellular-heating does not work, all the volume will be 
equally heated. This is again the declaration of the well- known rule: “the difference 
between the poison and the medicament is only their dose”.  
 
Figure 22. Both electrodes are always active, independently of its size or form. The current starts in one 
and ends on the other. The energy density is different, and many safety functions differ 
 
Figure 23. The selection mechanism of the optimally applied RF-current targets the cellular membrane, 
concentrates the energy in nano-range of the cell 
Generally, a certain power interval is necessary for optimal efficacy, both the too high and 
the too low are non-optimal. The cars form a trivial example: the cold engine needs more 
fuel to be heated up for its optimal use, but it must be cooled down and kept in a definite 
range of temperature by a cooling system for its optimal work.  
The average heating cannot produce high-efficacy. The high efficacy requests high 
selectivity for the accurate control of the process. The simple control of the average wastes a 
part of energy. This “waste” is expended energizing the particles, which are not involved in 
the desired process. The particles in the targeted process, which would like to have more 
power for the actual effect, have also the average only. Simple examples could be quoted 
from the everyday life again: when I would like to honor somebody’s excellent work, it 
would be inefficient to honor everybody in average, being sure that the person whom the 
honor is due is also among the members of the group.  
The proper selection has to choose not only the cells in general from the heated volume, but 
especially the malignant cells have to be selected from the target. This task could be solved 
using the specialties of malignant cells in comparison with their healthy counterparts.  
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3.1. Selection by Warburg’s effect (conductivity selection) 
As Otto Warburg discovered, the malignant cells behave completely differently from their 
healthy counterparts, [161], having mitochondrial dysfunction to produce ATP. (For this 
discovery a Nobel-prize was granted for him.) Warburg’s work nowadays has its 
renaissance [162], [163]; showing the validity of the dominance of non-mitochondrial 
(fermentative) way of ATP production. The fermentative way of the metabolic ATP 
production is anyway “ancient” chemical reaction, which was characteristic at the beginning 
of the evolution of life, when the oxygen, the general electron acceptor was available only in 
a small amount in the atmosphere. It is the fermentative way to utilize the energy of glucose 
converting it into lactic acid (CH3CHOHCOOH), producing only 2 ATPs in one cycle.  
The metabolism in healthy cells is mainly governed by the convertible energy-source of 
ATP. The citrate (Krebs) cycle by mitochondria, the “energy plant” in cells, produces 36 
ATPs with excellent efficacy with the help of oxygen (see Figure 24/a.). The fermentative 
ATP production is a low efficacy process in malignant cells, (see Figure 24/b.), however, 
(due to its simplicity) it can occur in large amount, its overall energy-flux can be higher than 
obtained from the high efficacy process.  
 
Figure 24. Differences in healthy and malignant cells 
The malignant cells are in frequent and permanent cellular-division. The energy-
consumption for the intensive division is higher than the energy requirement for the healthy 
cells in homeostasis. This is available only when the glucose intake is at least 18 times 
higher, because its ATP production is 18 times less than normal. This allows the cell to 
supply energetically all the normal processes and make the differentiation and 
development, the adaptation and evolution possible. This is a huge additional part of the 
glucose influx to the anyway high Warburg process. The higher glucose metabolism can be 
measured by positron emission tomography (PET) [164]. When we take the higher 
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reproduction (proliferation) rate of malignant cells into account, (which requests more 
energy than for the cells in homeostasis), the final products (“waste”) are produced 
intensively. Hence, these cells are surrounded by “waste” compounds, their extracellular 
electrolyte is denser in ions, and the pH in their vicinity is lower. Consequently, the higher 
metabolism increases the ion-transport and the ion-concentration in the area of the 
malignant cell, which lowers the impedance (gains the conductivity) of that volume. This 
irregular behavior can be measured and imaged by the Electric Impedance Tomography 
(EIT), [165]. One of the applications of this effect can be applied even in the prophylactics 
like mammography [166].  
In consequence of the physical differences, the malignant cells are distinguishable by their 
biophysical parameters; their electric properties differ from normal. The main differences are: 
 The efficacy of the ATP production in the cancerous cell is low. The large ATP demand 
for the proliferative energy-consumption allows less ATP for active membrane 
stabilization by K+ & Na+ transport, so the membrane potentiating weakens [167].  
 The cellular membrane of cancerous cells differ electrochemically also from the normal 
and its charge-distribution also deviates [168]. 
 The membrane of the cancerous cell differs in its lipid and sterol content from their 
healthy counterpart [169].  
 The membrane-permeability is changed by the above differences. In consequence of 
these, the efflux of the K+, Mg++ and Ca++ ions increase, while the efflux of Na+ 
decreases together with the water-transport from the cell. Therefore, the cell swallows, 
and its membrane potential decreases further [170]. (The efflux of K+ regulates the pH 
of the cell, takes the protons out from the cytosol). The concentration of Na+ increases in 
the cytosol, and parallel to this, the negative ion-concentration also grows on the 
glycocalix shell, decreasing the membrane potential and the tumor will be negatively 
polarized on average, [171]. This fact was well used for direct current treatment 
(electro-chemical cancer therapy (ECT)) by Nordenstrom and others.  
 The conductivity (σ) of the tumor tissue will be higher than normal, [172].  
The conductance (as a self-selective factor choosing optimal current path, see Figure 25.) 
ranges from 20% to 4000% difference between the healthy and malignant tissues. The data 
sporadically fluctuate, but generally the tumor has lower impedance than its healthy 
counterpart does! This is exactly what is used in the oncothermia technique.  
There are numerous proofs of the conductive selection.  
 In a simple theoretical investigation [173] an elliptical “tumor” is introduced into an 
otherwise homogeneous body. Making use of the appropriate Green’s function, the 
changes in conductivity between the tumor and the surrounding region can be 
determined.  
 A precise diagnostics has been established by careful calculation of electric impedance 
of human thorax as well [174], and the 3-D electrical impedance tomography is 
intensively studied, [165].  
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 The increase of the current density in the tumor can be visualized by the RF-CDI 
(radiofrequency current density image), which is a definite, MRI-conducted 
measurement of the real processes, [175], [176], [177], [178].  
 
Figure 25. Effective and automatic focusing of oncothermia is a strong selective factor of the tumor and 
the malignant cells 
Together with these effects, further add-ons are expected by oncothermia: the intensive heat 
transfer on the cellular membrane intensifies the ionic-transports [179], which (in positive 
feedback) changes the ionic motility and conductivity. In addition, the gain of the blood 
perfusion by the increasing temperature (below 39 oC) will lower the impedance (increase 
the conductance) [92], [180] which is an additional positive feedback selectivity at the 
beginning of the treatment. In the advanced cases, the blood-perfusion is increased by the 
neo-angio-genesis [181]. This extra perfusion (generally till T=39 oC) lowers the impedance 
(increases the conductivity), which is again a selectivity factor.  
The positive feedback of growing temperature effectively increases the conductivity, [182]. 
The measured gain of the selectivity is 2% in oC, [183], which is in the range of 3643 oC, 
that is 14% increase.  
3.2. Selection by Szent-Gyorgyi’s effect (dielectric selection) 
The living material is not an ordered solid. Contrary to the crystals [184], it is hard to 
introduce the co-operation. The living matter is in aqueous solution, which is mostly well 
ordered, nearly crystalline (semi-crystalline, [185]) in the living state. This relative order 
formed the "dilute salted water" into the system having entirely different mechanical, 
chemical, physical, etc. behaviors from the normal aqueous solutions. Indeed, the important 
role in the living systems of the so-called ordered water was pointed out in the middle of the 
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sixties, and later it was proven, [186]. At first the ordered water was suggested as much as 
50% of the total amount of the water in the living bodies [187]. The systematic investigations 
showed more ordered water [188], [189] than it was expected before. Probably the ordered 
water bound to the membrane is oriented (ordered) by the membrane potential, which 
probably decreases the order of the connected water. Consequently, it increases the electric 
permeability of the water [190], and so decreases the cell-to-cell adhesion and causing cell-
division and proliferation [190].  
According to the Warburg’s effect the metabolism gradually favors the fermentation in 
malignancy. The end-products of both the metabolic processes are ions in the aqua-based 
electrolyte. The oxidative cycle products dissociate like 6CO2+6H2O  12H+ + 6CO32- while 
the lactate produced by fermentation dissociates: 2CH3CHOHCOOH  2CH3CHOHCOO- + 
2H+. Assuming the equal proton production (by more intensive fermentation energy-flux) 
the main difference is in the negative ions. The complex lactate-ion concentration grows 
rapidly and increases its osmotic pressure. Keep the pressure normal, the dissolvent (the 
monomer water) has to be increased as well, seeking to solvent by non-ordered water. 
Indeed, it is measured in various malignancies that the water is changed to be disordered, 
[191], [192], [193], so in these cases the ordered water concentration in cancerous cells is 
smaller than in their healthy counterpart. Consequently, the hydrogen ionic transmitter 
becomes weak, the removal of the hydrogen ions becomes less active. This decreases the 
intracellular pH and the proton gradient in mitochondria, which directly worsens the 
efficacy of ATP production. To compensate the lowered proton-gradient, the membrane 
potential of mitochondria grows. This lowers the permeability of the membrane, decreases 
the mitochondrial permeability transition (MPT), which have a crucial role in apoptosis, 
[194], [195]. (The high mitochondrial membrane potential and low K-channel expression 
were observed in cancerous processes, [196].). These processes lead to apoptosis resistance, 
and for the cell energizing the ATP production of the host cell (fermentation) becomes 
supported. The free-ion concentration increases in the cytoplasm, and so the HSP chaperone 
stress proteins start to be produced. This process needs more ATP as well as it is anti-
apoptotic agent, so the process could lead to the complete block of apoptosis. Rearranging 
(disordering) the water structure needs energy [197]. It is similar to the way the ice is melted 
with latent heat from zero centigrade solid to liquid with unchanged temperature 
conditions. This drastic change (phase transition) modifies the physical properties (like the 
dielectric constant) of the material without changing the composition (only the microscopic 
ordering) of the medium itself.  
The decisional role of the two metabolic pathways (the oxidative and the fermentative) was 
studied by Szent-Gyorgyi [190], having an etiology approach and using additional 
formulation. His interpretation describes the cellular states by two different stages. The 
alpha-state of the cell is the fermentative status, (see Figure 26.).  
This was general in the early development of life, when free oxygen was not available. The 
aggressive electron acceptor was not present [198]. In this stage, only simple, primitive life 
forms could exist. The main task was to maintain life with their unlimited multiplication. 
This state was only reproduction oriented, to develop complex structures and complicated 
 
Local Hyperthermia in Oncology – To Choose or not to Choose? 29 
work-division was not possible. All the living objects in alpha state are autonomic, they 
compete with each other and cooperative communication does not exist between them. With 
the later presence of free oxygen beta-state of life was developed. The oxygen made it 
possible to exchange higher value of electric charges, the unsaturated protein allowed more 
complex interactions and started the diversity of life. The cells, in this state, are cooperative, 
the task from the only multiplication became more complex, including the optimal energy-
consumption, the diversity for optimal adjustment to life. This is the phase, which 
integrated the mitochondria for oxidative ATP production, and so produced the energy in 
high efficacy.  
 
Figure 26. The dielectric (order) differences between healthy and malignant cell-environments 
The historical development of the life from alpha- to beta-stages has been generalized [190], 
introducing the same states for the actual stage of the cells in developed complex living 
systems. (Further on Greek letters α and β will be used to denote those states.)  
The highly organized living objects are mainly built up from cells in β-state. Their cell-
division becomes controlled. This control is mandatory, because the division needs 
autonomic actions, the cooperative intercellular forces slack, a part of the structure has to be 
dissolved and rearranged, so the cell in division state is again in non-differentiate state, 
similar to the α one.  
The α state is the basic status of life. In this status the highest available entropy is 
accompanied by the lowest available free-energy. All complex living systems could easily be 
transformed into this basic state when it becomes instable. Then by the simple physical 
constrains (seek to low free energy and to high entropy) the cells try (at least partly) realize 
the α-state again. Once more, the system (or a part of it) contains cells with high autonomy 
and proliferation-rate. By simple comparison of Szent-Gyorgyi’s states and Warburg’s 
metabolic pathways are common: the α- and β-states correspond with the fermentative and 
oxidative metabolism, respectively. In other words, α-state prefers the host cell ATP 
production (anaerobic) but when the perfect mitochondria function works, that is β-state. 
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These states are mixed (the cell works in both metabolic activities) and it is only a question 
of quantity in their category. In normal homeostasis the β-state characteristics is about 70%. 
The actual balance fixes the actual status. The balance could be formulated by the cell status 
of co-operability (α  β); or formulated by metabolic ways (fermentation  oxidation) or 
could be formulated with the acting parts of metabolism: (host-cell  mitochondrion). The 
meaning of all the formulations is equal: the actual energetic state is described. Note the 
interesting relation between the energy flux and co-operability. The high energy-flux makes 
the cells less cooperative and more primitive, while the low energy-flux makes the cells not 
only cooperative but also sophisticated, highly effective in energy production and in 
environmental adaptation as well. (It also has interesting similarity with the organizing of 
societies [199], but it is outside our present topic.)  
Differences of the metabolic processes of vertebrates and invertebrates are (terrestrial, 
pelagic and benthic) well mirrored in the scaling exponent, [200]. The benthic invertebrates 
(n=215) have the lowest average scaling exponent (pmean=0.63, [near to ⅔], CImean=0.18), which 
metabolizes basically on anaerobic way, [201], while all studied animals (n=496) have 
(pmean=0.74, [near to ¾], CImean=0.18), [200]. The scaling of the metabolic activity is also 
different in mitochondrial or non-mitochondrial metabolism. The mitochondrial metabolism 
is always aerobic, its scaling exponent is nearly p=¾, [202], [243], while the non-
mitochondrial respiration scaling is near to ⅔ [203].  
One question arises immediately: what mechanism makes control on the balance of β-and α-
states in the highly developed living objects? The electromagnetic behavior of electrolytes in 
living systems might give us the answer [204]. The cooperative cells mostly run on oxidative 
metabolism, and their division is controlled by the cells in their neighborhood. There are 
two basic reasons for normal cellular division, and it could be a regular division keeping the 
homeostasis of the given tissue, replacing the elder cells with young daughter cells, or it 
could be a forced, constrained division (like by wound-healing, reparations, embryonic 
development, constrained tissue-specific cell-production, etc.). The questions are: which 
process starts the division and which finishes it? 
It is easy to start the division. The cell-division certainly requires extra energy, much larger 
than it is in normal conditions.  This could be a mechanism described above: the changing 
concentration of one or more components needs more dissolvent, which is provided by the 
order-disorder transition of the intracellular aqueous electrolyte as well as the osmotic 
water-flow through the cellular membrane. The concentration misbalance can be created by 
outside stimuli (like injury currents) or by inside enrichment of a component due to aging or 
to metabolic misbalance. The order-disorder water transition does not only change the 
hydrogen-ion diffusion, but it also changes the dielectric constant of the medium [204]. The 
more disordered liquid increases the dielectric constant (in other words, the ability of 
electric isolation increased). This is directly connected with the promoted charge-division 
and the suppressed polymerization activity in subcellular level, creating positive feedback 
to the fermentation processes. The balance is broken, and turned to the phase where the α-
state is dominant. It is not necessarily a malignant transition. This happens with any regular 
cell division as well. This is the “motherhood” of the cell, making it possible to “deliver” the 
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daughter cells. The “individualism” of the mother-cell is explainable with the extreme high 
energy demand of the division process. When the daughter cells appear, they must accept 
the previous order. Their “infancy” is normal, as the “babyhood” is normal after the 
deliveries. The “babyhood” period has to be limited in time, and the newly born cell has to 
find its normal collective function. Consequently, the process might go wrong, if after 
finishing the division, the daughter cells do not find the way of the co-operability and the β-
state again. When it is not the case, the cells are blocked in the α-state, their proliferation 
becomes uncontrolled. This unfortunate case, however, is not a simple process originated 
from one single defect. It is a disturbance of a complex controlling mechanism [190], which 
well correlates anyway with the single “renegade cell” concept [205], showing a long 
process to produce “a renegade cell” as the ancestor of the billion-cell group called cancer. 
According to the epidemiological research, for a complex damage to occur and for the 
cancer to develop at least five different mutations have to be coincidently present to be 
malignant. [206].  
Again we are back to the main question: what is the mechanism to re-establish the β-state 
after the division of the cell. We think, that the down-regulation of the energy-flux has the 
same active elements as the up-regulation had at the start of the division. The clue is again 
the order-disorder transformation in the aqueous solution. As we told, at the beginning of 
the division, a huge energy has to be ready to supply the process, a large number of proteins 
and other cellular elements (lipids, enzymes, etc.) have to be produced, and all need ATP 
desperately. In α-sate the conditions are ready for that. When the division is over, two new 
daughter cells appear, the energy-consumption drastically drops to the normal level of the 
two cells. The doubled cytoplasm and all the cellular elements had enough dissolvent 
capacity even in the ordered water case. The hydrogen-bridge proton bifurcation can be 
reorganized, there are no opposite environmental driving forces. The sudden doubling of 
the cellular elments cools down the liquid to solid. It goes through the same phase transition 
(disorder-order transition) as it was (only the opposite direction) when the division started. 
This again (like in the liquid phase transitions) lowers the free energy, and in all (together 
with the environment, where the extra heat is radiated) increases the entropy. Note, the 
entropy apparently decreases (information build up) in the local cellular level, the overall 
conditions have to be considered for the full picture. 
As we showed, the metabolic pathways could drastically modify the development of the 
cell, and it could be the primary source of the malignant deviations. The balance of the 
oxidative and fermentative metabolism tunes the cellular ability to behave collectively or 
constrict autonomy, being individual. These conditions of course well depend on the energy 
(and signaling) exchange of the cell with its actual environment. The intracellular transport 
properties also have to be different at changing metabolic pathway. The intensive energy 
flux of the fermentative metabolism increases the liberated heat in the cell, and so the 
temperature gradient between the extra- and intracellular compartments. The growing 
temperature difference could reach a critical threshold, when the heat flow turns from 
conductive to convective [207]. (This phenomenon works like the well-known Benard 
instability, [208].) The convective way promotes the ionic flows through the cellular 
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membrane increasing the glucose permeability and so supports the fermentation way of 
metabolism together with the changes of the intracellular circulations, [209], [210]. This 
complex change could down-regulate the mitochondrial oxidative metabolism.  
At the divisional processes the intracellular flows and all pathway activities are probably 
higher both at regular and at malignant cell-division. Possibly the order-disorder transition 
of the aqueous solution also has a role in the changes [211].  
However, finishing the division, the daughter cells are separated, a higher surface suddenly 
appears and the separated volumes limit the intracellular flows and change the order of 
structure as well. It decreases the gradient through the membrane. This regulates the heat-
flow through the cellular membrane and changes the energy-exchange from convective to 
the conductive one again [207]. The conductive heat-exchange does not support the 
intensive diffusion of the large-molecule glucose, so the oxidative way becomes necessary 
and regular. The two daughter cells have less than half energy-consumption (each) than it 
was requested by the mother cell. It is because the mother cell was large (doubled its 
volume) and was intensively producing various elements to complete the daughter cells. 
Instead of the division conditions where the high energy-request gained the energy-demand 
and preferred the high-energy flux fermentative metabolism, the normal homeostatic 
conditions will dominate again.  
The significantly larger permittivity and conductivity in tumor-tissue in vitro is explained on 
this basis, [212]. Both the conductivity and dielectric differences between the healthy- and 
tumor-tissues at the applied 13.56 MHz frequency in most cases of the malignancies are over 
15% [213], [172]. It is clinically proven, that the cancerous and healthy tissues of the hepatic 
tumors are significantly different [214]. Also the VX-2 carcinoma can be measured [215]: 
rabbit-liver at low frequency in vivo had a conductivity 6-7.5 times higher, permittivity 2-5 
times lower than in the healthy parts (impedance difference is about 600%), while for 10 MHz 
region it is 200%. With impedance tomography we can make a distinction between the living 
and necrotic malignancy as well, [214]; both the conductivity and permittivity are higher in the 
malignant liver, but the frequency dependence of necrotic tissue differs.  
The dielectric properties are also distinguishable by the water content of the malignant 
tissue, which is higher than that of their healthy counterpart. The proliferating cells control 
their cell-volume by their water content, in the malignant growth [216], and this effect 
increases the conductivity and generally the dielectric properties in the given tissue.  
The high dielectric constant allows the additional selection (focusing): the higher dielectric 
constant absorbs more from the RF-energy, (see Figure 27.).  
3.3. Selection by order-disorder effect (fractal physiology selection) 
The non-equilibrium phenomena is well formulated in the description of the Avrami-
equation [217], pioneered by Kolmogorov [218], by Johnson & Mehl [219] and by others, 
[220], [221]. The description could serve as a mathematical model for different biological 
processes, [222], [223]. Experimental data which were collected by Cope [224], [225], and by 
others [226], [227], show a definite universality to describe the real processes. 
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Figure 27. The disordered state could absorb more form the applied electric field energy than the 
ordered one 
The modern physiology is an essentially interdisciplinary subject, combining the knowledge 
of various fields, like the electronic structure approach of solid-state physics (e.g. Szent-
Gyorgyi, [228], [229]), the superconductivity (e.g. Cope, [230]), the electromagnetism (e.g. 
Liboff, [231], [232]), the thermodynamics (e.g. Schrodinger, [233], Katchalsky & Curran 
[234]), etc. Various modern approaches were developed in the last decades based on this 
complexity, like self-organization ([235], [236],), fractal physiology ([237], [238], [239], [240]), 
and the bioscaling ([241], [242], [243]).  
The healthy cells work collectively, their energy-consumption as well as their life-cycles and 
the availability of resources are controlled collectively by the various forms of the self-
organizing, [244], [245]. The healthy cells are organized this way, their standard cycles, 
reactions and structures are complexly regulated in both internal and external areas. The 
healthy cells have special “social” signals [246] commonly regulate and control their life. 
They are specialized for work-division in the organism and their life-cycle is determined by 
the collective “decisions”. 
What makes the difference in the absorption? It is the missing collective order in 
malignancy. The cancerous cells behave non-collectively; they are autonomic. They are 
“individual fighters”, having no common control over them, only the available nutrients 
regulate their life. The order, which characterizes the healthy tissue is lost in their malignant 
version, the cellular communications are missing [247].  
The malignancy has a special fractal structure, which can be identified by impedance 
measurements on Erlich solid tumors [248]. This structure (due to its definite percolative 
self-similarity) is a better conductor [249] than the non-fractal healthy tissue.  
The living matter has a highly self-organized hierarchical structure. It is in non-equilibrium 
and its processes are non-stationer, [250]. The subsystems of living organisms are multiple, 
connected with various physical, chemical and physiological processes and the interacting 
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signals change in a wide range. The simplest biological systems show various processes on 
different time-scales in vivo, which are connected by bio-scaling [241]. There are no two 
identical living objects exist, the living matter is variable, changeable and mutable, [240]. It 
differs from the lifeless [251]. While the thermal and quantum fluctuations in lifeless are 
negligible by the size of the system; the living object has a high number of homologue 
phase-states randomly transformed and altered into each other, they mutate by the time, 
which is unchanged among identical environmental conditions. In contrast, the permanent 
and immanent change makes the living object possible for adaptation, for mutation and for 
natural selection. This dynamism appears in the change of the confirmation state of proteins 
optimizing the enzymatic reactions of life. Due to these fluctuations, the living matter is 
“noisierand” because of its self-similar [252] and self-organized [244] behavior, its power-
spectrum shows pink-noise (1/f noise), [238], [239].  
The highest deficiency of information (highest entropy) is achieved by the noise, which has 
Gaussian distribution [253] (Gaussian noise). Because the effective power-density of pink-
noise is constant in all characteristic scales, the Gaussian pink-noise then has maximal 
entropy in all the scales. The living system has special fractal dynamism, [254], in 
consequence of its self-similar stochastic behavior, it fluctuates by the pink-noise, [255]. The 
maximal entropy of Gaussian pink-noise allows an important conclusion: the noise of the 
living state has maximal entropy (stable dynamic equilibrium) in all of the characteristic 
scales.  
The cell motility probed by noise analysis of thickness shear mode resonators [256]. The 
noise analysis of the electric currents has become a new tool in the field, [240]. Absorption 
and fluctuations of giant liposomes were studied by electrochemical impedance 
measurements, [257].  
Oncothermia uses these new approaches to fit in the best curative performance. This new 
approach (the fractal physiology) is applied for oncothermia. The carrier electric field 
delivers the time-fractal structure to the tissues enhancing considerable the selection 
between the connected healthy cellular community and the individual autonomy of the 
malignant proliferation.  
The disordered structure of malignancy is a good absorbent. To show it again by a simple 
example: when somebody’s hair is in order, the comb slides through the over-combed hair. 
However, when the same hair is disordered, combing is able even to cut out the hair by their 
energy-absorption mechanisms. In malignancy the disorder makes the same energy-
absorption process, (see Figure 28.). 
The order-disorder selection method is similar to the process when the light goes through 
the windows-glass (see Figure 29.). When the glass is transparent to that specific set of colors 
(visible light, definite interval of frequencies) its absorption is almost zero, all energy goes 
through it. However, when it has any bubbles, grains, precipitations etc. those irregularities 
will absorb more from the energy, their transparency is locally low, their energy absorption 
is high, they are heated up locally. It is a self-selection depending on the material and the 
frequency (color) which we apply in the given example.  
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Figure 28. The malignant absorption selects by the disorder of the cancer, having no transparency for 
the well-chosen modulated RF carrier frequency (It is a patented method and know-how of 
oncothermia.) 
 
Figure 29. The transparency of the glass. In full transparent case all the energy goes over the glass (a), 
but when the glass has aggregates, those absorb a part of energy (b), and they will be hotter than their 
environment 
This is the effect, which is used by oncothermia with some modulation. The carrier 
frequency delivers the information (modulation frequencies), for which the cancer cells are 
much less “transparent” than their healthy counterparts are. Malignant cells are heated up 
by the selectively absorbed energy.  
3.4. Effect of electric field on malignancies 
The physiology is an interdisciplinary subject. It uses numerous principles and discoveries. 
Its electronic structure approach derived from solid state physics (e.g. Szent-Gyorgyi, [228], 
[229]), the superconductivity approach (e.g. Cope, [258]), the electromagnetic resonances 
(e.g. Liboff, [259], [232]), the thermodynamics of life (e.g. Schrodinger, [233], Katchalsky & 
Curran [234]), etc. are all parts of the physiology, and make it really complex like the 
phenomena of the life itself is.  
The important category of the hyperthermia was generated by electric fields [260], 
[198],which is even a hot topic in science presently[261], [262]. The electric conductive 
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heating started in the late 19th century is called “galvanocautery” [263]. The method was 
further developed by D’Arsonval, introducing the impedance (alternating current [AC], later 
higher frequencies, even spark-generated currents) calling it “Arsonvalization”, [264], and 
later a more modernized method was the “fulguration” [265]. The Arsonvalization method 
had fantastic popularity at the turn of the 19th-20th centuries, developing three different 
branches: the interstitial hyperthermia, including the galvanic heat-stimulation (electro-
chemical-cancer-treatment), the ablation techniques and the capacitive coupling. The first 
capacitive coupled device on conductive basis was the “Universal Thermoflux”. It was 
launched on to the market by such a giant of the electric industry in that time as Siemens, 
which was later further developed, and the new device by the name “Radiotherm” was 
launched on the market in the early 1930s. The first start of the new capacitive-coupling 
technologies was in 1976 by LeVeen [266] and has been widely applied since then [267], 
[268], [74]. Many hyperthermia devices use capacitive coupling since its treatment is easy.  
An electric field application without an increase in temperature (using less than 5W power) 
has also been found effective against cancer [269], [270], [271], [272], [273], [274], by using 
galvanic (DC) current applications. The control of these treatments is the tissue-resistance 
and the quality parameter is the applied charge load, [275], [276]. Numerous devices were 
developed and applied widely, but the expected breakthrough result was missing. An 
entirely new line was started with Professors Rudolf Pekar, [277], [278], [279], Bjorn 
Nordenstrom [273], [274] and Xin You Ling [280], [281], [282]; and continued by others [283], 
[284], [285], [286], [287], [288], [289]. Remarkable results were produced by this method; and 
the biological mechanisms involved in electromagnetic field are intensively investigated 
[290], [72], and the effect of electric field is studied on various side of its complex behavior, 
[261], [262]. Recently, the effect of electric field has been used for special therapies in 
oncology, [291], [292], [293], [294]. 
A sophisticated study was performed to study the synergy of temperature and modulated 
electric field [295]. The model was HT-29 human colorectal carcinoma cell-line being 
xenografted to nude mice (BALB (nu/nu)). For comparison we performed low temperature 
oncothermia experiment, where the bolus of the upper-electrode was cooled down. The 
intensive cooling kept the tumor near the physiological temperature (38 oC) while the 
oncothermia field was identical with the heating conditions of 42 oC. The result is 
surprisingly interesting (see Figure 30). The effect of electric field made nano-range heating 
only, the overall temperature had a minor role in the cell-killing mechanism.  
3.5. Other selection factors 
There are numerous selection effects existing to distinguish the malignant cells. Here we 
comprehensively list some of them.  
The missing cell-junctions and the characteristic isolation of the malignant cells from each 
other [247], [296] create a free extracellular pathway between the cells, definitely increasing 
the conductivity of the extracellular electrolyte. Furthermore, the decrease of the epithelial 
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barrier function (tight-junction permeability changes) can be measured by electric 
impedance measurement, [297].  
 
Figure 30. Oncothermia was 3 times more effective than hyperthermia on the identically high (42 oC) 
temperature. However, cooling down the tumor during the treatment, the death-rate decreased only 
slightly, exceeding more than 2 times the classic hyperthermia on high temperature 
The special membrane effect (rectification on membranes, [298]), is also a factor of the 
cellular selectivity of cancer by RF electric field. The impedance measurement is useful for 
the control of other treatment modalities. It adequately measures the distortion, made by 
irradiation [299], and the drug-effect can also be controlled, [300]. Such usual practice, like 
following the wound healing, is also objectively traceable [301]. Bioimpedance vector 
pattern can distinguish cancer patients without disease versus locally advanced or 
disseminated diseases [302].  
The impedance measures selectively, differentiates between the cancerous and healthy 
tissue, and is able to distinguish the extra- and intra-cellular electrolyte. Selective impedance 
measurements are provided clinically as well. Many comparative studies have been provided 
for malignant tissues, however, the results are not identical; the measurements very much 
depend on the conditions. (This is a trivial consequence of many factors, which we listed 
above.) However, all the studies measured lower impedance in the tumor than in their healthy 
counterpart in all of the tissue and staging of the tumor, in vitro and in vivo as well.  
Hyperthermia increases biochemical reaction rates [303] and therefore the metabolic rate as 
well. The metabolic heat production of tumor depends on the doubling time of its volume 
[304]. The high metabolic rate keeps the temperature for tumor tissues higher than its 
neighborhood, [305]. This works as selection factor for heating of tumor tissue. Therefore, in 
case of 6 oC increase the amount of growth will be 1.8-times higher [306] than its healthy 
counterpart.  
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It has been long known that hyperthermia can cause the softening or melting of the lipid 
bilayer [307], [308], [155], it can change lipid-protein interactions [309], and it can denature 
proteins [310]. All of these events can arrest the cell-cycle of the tumor.  
Heat-treatment cause structural alteration in transmembrane proteins, causing a change in 
the active membrane transport and membrane capacity [311] leading to substantial changes 
in potassium, calcium, and sodium ion gradients [312], membrane potential [313], [314], 
cellular function [315], [316], and causing thermal block of electrically excitable cells [317], 
[303]. The thermo tolerable cells have significantly higher (~15%) membrane potential than 
the naïve cells [314], and the difference rapidly grows by the elapsed time at 45°C.  
In chemo-thermo-therapies the role of chaperone proteins is important. Chaperones (stress- 
or heat-shock-proteins) are highly conserved proteins, which are vital in almost every living 
cell and on their surfaces during their whole lifetime, regardless of their stage in the 
evolution, [318]. Any kind of change in the dynamic equilibrium of the cell life 
(environmental stresses, various pathogen processes, diseases, etc.) activates their synthesis 
[319]. Excretion of the chaperones is the ‘stress-answer’ of the cells to accommodate 
themselves to the new challenges. As a consequence of the stressful ‘life’ of malignant cells, 
the molecular chaperones are present in all cancerous cells [320], [321], [322] to adapt the 
actual stress to help tumor-cell survival. Moreover, the shock-proteins are induced by every 
oncological treatment-method, which are devoted to eliminate the malignancy: after 
conventional hyperthermia [323], after chemotherapy [324], after radiotherapy [325] or even 
after photo-therapy [326] intensive HSP synthesis was shown. By the stress adaptation the 
induction or over-expression of the stress proteins generally provide effective protection of the 
cell against apoptosis [327], but their extracellular expression acts oppositely: it makes a signal 
to the immune system on the defect of the actual cell [328]. Furthermore, induction of various 
HSPs (HSP27, HSP70, and HSP90) was observed in numerous metastases and the HSP90 
homologue, GRP94 may act as a mediator of metastasis generation. HSP generally degrades 
the effect of the hyperthermia therapy because it may increase the tumor cell survival, and its 
massive induction may generate the tumor thermo-tolerance and in parallel drug- and radio-
tolerance. Heat treatment can also lead to multi-drug resistance [329].  
Non-temperature dependent effects (mainly field stresses) can also produce chaperone-
synthesis [330]. The HSP manifestation in the biopsies might give a good clinical indication 
for the treatment response [331].  
On the other hand, the chaperone HSP70 assists to freeze the actual dynamic equilibrium 
(the “status-quo”) and so tries to re-establish the cellular communication in the extra-cellular 
electrolyte [328]. It is shown that their expression on the cell-membrane gains the apoptotic 
signals and enhances the immune reactions, [328]. HSP participates in the activation of the 
p53 tumor-suppresser [332] and has been associated with the tumor-suppresser 
retinoblastoma protein [333].  
Recently, numerous scientific theories have also concentrated on the significance of 
thermally induced non-thermal effects, such as heat-shock protein (HSP) production [334], 
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[335]. Development of the thermo-tolerance is one of the suppressors of hyperthermia 
efficacy [323]. From the point of view of the thermo-tolerance, one of the most prominent 
chaperone proteins is the HSP72. The concentration of this HSP is 5-10 times lower in the 
healthy cells than in the malignant ones, and both grow by the heat-treatment [336]. 
However, responding to the heat treatment, their concentration in healthy cells is: 
multiplied by 8 or 10, while during the same heat treatment the HSP72 multiplication 
creates only 1.2-1.5 times higher concentration in malignant cells, [323].  
4. Cellular effects – To kill or not to kill? 
Like Nobel-laureate A. Szent-Gyorgyi formulated: from the point of view of life, it is not 
interesting how the monkey goes through the forest, but it is essential how the forest goes 
through the monkey [as nutrition]. In hyperthermia we have to have the same change of 
paradigm: it is not important how the incident energy increases the temperature, but that is 
essential how the incident energy changes the structure and the chemical bonds in the 
targeted tissue.  
4.1. Apoptotic cell killing  
The above described mechanism targets the membrane of the malignant cells, and excites 
numerous pathways essential for the cellular fate, (see Figure 31.). The excitations have 
serious consequences on membrane:  
 Induces apoptotic signal 
 Forms membrane-HSP 
 Makes the membrane more transparent 
 Forms higher motility of membrane domains 
 Rebinds the E-cadherin adherent connections 
 Damages the  cell-membrane 
 Rectificates, demodulates the modulated signal (stochastic effects are involved) 
The effects in the cytoplasm are also remarkable. The transmembrane temperature gradient  
 
 Dilutes the cytoplasm 
 Develops higher intracellular pressure  
 Activates apoptotic pathways 
 Activates death receptors 
 Suppresses the proliferation 
 Arrests the DNA replication 
These effects were shown in multiple, different experiments. The basic repeated phenomena 
are the time-delay of the action, selection and tumor destruction of oncothermia became 
trivial hours after the treatment (see Figure 32., [337]). The numerous apoptotic bodies show 
the character of the process.  
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Figure 31. Numerous pathways are excited 
 
Figure 32. Morphological observations show extended cell-destruction in the large volume of the 
tumor (field effect is active, temperature doesn’t change, self-focusing). The destruction has a time-
delay, hours are requested for the natural processes to be well- activated to fight. The numbers 
indicated on the mice are the hours after the single shot of 30 min oncothermia treatment, (HE Staining). 
(a) full cross section of the tumor, (b) magnification of the tissue by 100x 
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The time delay indicates the long-duration processes, which were identified as programmed 
cell-death (apoptosis), by various investigations: macro- and micro-morphology, enhanced 
activity of p53 tumor-suppressor, cleaved caspase 3 involvement, Tunel reaction, DNA 
fragmentation (laddering), etc. (see Figure 33., [337]). The rebuilt external apoptotic 
pathways are shown by reestablished E-cadherin connections, by enreachment of beta-
catenin and its relocalization into the nuclei, by connexin induction, by activation of death-
toll receptors, like FADD, FAS, DR-5, etc.  
 
Figure 33. External electromagnetic field activates signal transduction pathways, concluding to 
apoptotic cell-death. (Oncothermia treatment (HT29 colorectal xenograft model) 
This apoptotic process is non-toxic (no inflammatory reactions afterwards) and promotes 
the immune reactions (works parallel with these).  
The cellular selection is proven by various experiments. One of these is the definite selection 
of malignant cells in co-cultures, [338]. The effect on healthy human keratinocytes (HCK) co-
cultured with human fibroblasts (see Figure 34.) was marginal, and was regenerated by the 
time. The co-culture with immortalized (but not malignant) HaCaT keratinocytes is affected 
slightly, but the malignant A431 cell-line was selected from the co-culture (see Figure 35.). 
The time-delay and the relocalization of the beat-catenin to the cell-nuclei is shown in vitro 
(HepG2 cell-line) and in vivo (HT29 xenograft) shown in Figure 36. [339].  
The time delay is shown in the Tunel reactions (see Figure 37.), indicating the late apoptotic 
phases dominantly after 24 h of the single shot treatment. 
An interesting measurement was provided by Ki67 proliferation marker, measured in the 
living tumor part after the single-shot treatment of oncothermia, (see Figure 37, [340]). The 
surviving, living malignant cells in the treated tumor had definitely and significantly 
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suppressed Ki67 marker compared to its untreated counterpart in all the time-scale 
investigated.  
 
Figure 34. Co-culture with normal human skin fibroblasts as a model of a squamous carcinoma 
growing within connective tissue cells (100.000/ml) were exposed to oncothermia. Samples were 
incubated for 24 h at 37°C, fixed and stained with crystal violet. Cellular metabolic activity was 
measured using the MTT assay (standard colorimetric test) and quantitated at 630 nm. (Data represent 
the mean value ± S.E.M. of 4-6 separate experiments assayed in triplicate, but some experiments were 
repeated up to 12 times to obtain reliable data.) 
 
Figure 35. The selection of the malignant cells is effective in the co-culture of the malignant A431 
human keratinocytes and healthy human fibroblasts. [a – before oncothermia, b – after oncothermia]. 
The healthy cells remain intact, while the malignant cells are damaged and cleared. (Experiment is 
described in Figure 34.) 
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Figure 36. The beta-catenin relocalization into the nuclei 
 
Figure 37. TUNEL assay: enzymatically label the DNA fragments resulted by apoptotic process 
 
Figure 38. Colon26 (murine colorectal cancer) cell line derived allograft (CID mice), single shot. (Ki-67: 
proliferation marker protein, expressed in the nuclear membrane only in the dividing cells.) 
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The cleaved Caspase-3 (as important part of the apoptotic pathway) was activated (see Figure 
39., [341]), as well as the death toll receptors became overexpressed (see Figure 40., [341]).  
 
Figure 39. HT29 human colorectal carcinoma cell-line xenograft model in nude mice. Caspases, or 
cysteine-aspartic proteases or cysteine-dependent aspartate-directed proteases are a family of cysteine 
proteases that play essential roles in apoptosis (programmed cell death), necrosis, and inflammation 
(the red line is for the reference value) [Reference: untreated control]  
 
Figure 40. HT29 human colorectal carcinoma cell-line xenograft model in nude mice. Death receptor 
activity (the red line is for the reference value) [Reference: untreated control] 
4.2. Suppressing the dissemination of malignant cells 
Oncothermia is different from this point of view as well. It blocks the dissemination, avoids 
their motility due to the lazy connections with the tumor. Oncothermia makes it by the 
reestablishing the cellular connections (see Figure 41. [337]), which is also great success to 
save life. The built up connections can force not only the sticking together, but make bridges 
between the cells for information exchange to limit the individuality and the competitive 
behavior of the malignant cells.  
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Figure 41. Oncothermia can reestablish the adherent cell connections (E-cadherin and β-catenin) as well 
as the gap-junctions (Connexin-43). These could reestablish the cellular communication and can stop the 
dissemination of tumor cells 
This “gluing mechanism” is not only important for the external apoptotic signal, but makes 
the malignant cells less mobile, their motility is reduced and the dissemination risk is 
decreased.  
4.3. Action on far distant metastases  
The main danger of malignancies is the metastases, attacking the organs which are crucial 
for life. When the tumor grows somewhere without endangering the important systems like 
the respiratory system, central nervous system, cardiovascular system, etc., it is not life-
threatening. These tumors are local (benign or early malignant), their elimination is possible. 
The real life-threatening danger is the malignancy, when the cells are disseminated from the 
tumor-lesion by the various transport systems (lymph, blood), or their effect becomes 
systemic by one of the general mechanisms of the organism.  
The heavy life-threatening effect of metastases has been observed on statistical basis on 
colorectal adenocarcinoma collecting data for 15 years [342]. The long- term (10 years) 
survival was around 90% when no metastases were present, 60% in case of regional 
metastases and only 15% when distant metastases were developed in the patient. The blood-
transported cells can be blocked easily by the brain, lung, kidney, liver, etc., causing fatality. 
The challenge of the treatments is to recognize the tumor early, to avoid the metastases, 
and/or to block the dissemination as much as possible.  
In veterinarian clinical trial of dogs having osteosarcomas without evidences of metastases, 
the local radiation combined complementary with whole body hyperthermia was studied. 
The result was surprisingly bad [343], [344]: the combined treatment was not effective on the 
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primer tumor, but rapid and massive metastases were developed in far distance organs 
including the lung. This blocked the research in this direction, the veterinarian application 
of the hyperthermia even in combined therapies was not plasticized in veterinary field. 
One of the interesting, and so far not completely understood process, is the systemic effect 
of the local treatments called abscopal (out of the target) or bystander effect [345]. This 
phenomenon shows a systemic effect only by local treating, see Figure 42. The effect was 
shown in mice experiments [346], see Figure 43, and also in human, see Figure 44., [347]. 
 
Figure 42. The mice have two distant tumors in left and right femoral region. The growths of the 
tumors are equal. When we treat the mice systemically with immune supporters, no change can be seen. 
When we treat the A tumor locally with oncothermia, that tumor does not grow so quickly as the 
reference C. However, when we apply the systemic immune therapy and the local oncothermia for the 
only A-lesion, surprisingly, the C lesion is also suppressed 
 
Figure 43. E. coli LPS sc. to the dorsal region of the animal 24 h before the oncothermia treatment. 
100ug LPS in 100uL Salsol solution. 30 min oncothermia with pink noise AM modulation (41-42°C 
tumor core temperature) Sampling: animals were sacrificed 72 h after the treatment 
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Figure 44. Investigator: Prof. Dr. Seong Min Yoon, Institute: Division of Hematology-Oncology, 
Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University, S.Korea 
Patient: SAsc, 72 y, male, Primer-tumor: Non-small cell lung cancer; Size: 9.5 cm right middle lobe, 
Metastases: in sentinel and distant lymph-nodes, Tumor-classification: cT2 cN2 M0, stage IIIB, 
Treatment: trimodal protocol: 28x1.7 Gy; support: 250 microgram Leukine and Oncothermia 6x; Only 
the primer tumor was locally treated 
4.4. Some clinical results  
Oncothermia has a long-time history with large number of documented case reports and 
clinical trials [160]. During more than 20 years 43 studies were performed involving more 
than 2000 patients altogether from 14 clinics in 4 countries (see Table 1.) Details of the 
clinical effects are summarized in the publications as well as in the specialized monograph 
[160].  
The clinical trials of oncothermia are dominantly retrospective. To develop randomized 
clinical trials is a challenge for patients. Patients do not agree to be in the control-arm at any 
case. In most of the cases they are registered for oncothermia because the other methods 
(conventional gold standards) failed. In these cases progression could occur anyway due to 
drug-resistance, organ-overload (kidney, liver, etc.), tumor-relapses, psycho-resistance, etc.  
The advanced cases at the conditions described above emphasize not only the complexity of 
the individual situation of patients, but also underlines the fact that oncothermia is applied 
as the facility of the “no other is possible” many time hopeless cases providing over 3rd line 
treatment approach. This high-line treatment process is in general palliation (the first goal is 
to provide acceptable quality of life), which is an important factor for oncothermia as well. 
However oncothermia even in these advanced situations has curative value, and makes 
curative therapy in 3rd-line or over. The professional literature clearly shows the rare facility 
of the evidence-based clinical trials for these high-line treatments. Other evidences have to 
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be shown when randomized controlled trials are not possible, [348]. The challenges of 
evaluation appear forcefully in  case of patients with advanced stages having inoperable (or 
partly resected) tumors, having relapsed malignancies, patients who are resistant on the 
gold-standard treatments, etc. Oncothermia is facing to this challenge as well.  
We have to make special attention evaluating of the clinical results performed by 
oncothermia. The complications make definite challenges to objective evaluation. The main 
challenges are: 
 Oncothermia is applied in higher (usually third and subsequent) treatment-lines, 
boosting or resensitizing the effect of the conventional therapies. Oncothermia is mostly 
applied in cases when the conventional therapies fall. In most of the cases oncothermia 
therapy is applied when the patient has/is  
- Inoperable lesion  
- Radio-resistant 
- Chemo-resistant (refractory) 
- Improper blood-counts 
- Liver-failure 
- Kidney failure 
- Psycho-resistance 
In most of the cases the complex combination of the above problems occurs. Due to 
these conditions, oncothermia is applied in higher line of the therapies. This sequence of 
the treatments is mostly determined by the individual decisions of the physicians [349], 
usually without having help from any evidence based statistical approvals. 
 Usually it is applied in palliative care; many patients are in terminal phase. This patient 
care has very limited statistical evidence based trials; the medical decision-making 
processes are usually well tailored to the individual patients [350], [351].  
 Only few controlled randomized clinical trials are available for oncothermia. The results 
have to be concluded from observational studies and from the historical and data-base 
comparisons. USA- and EU-databases (SEER [352], Eurocare [353]) are mostly used. 
Due to the not solved problem between the hypothesis check confidence of evidence 
based medicine and the observational studies [354], [355], this data-comparison is 
acceptable. Make the result as objective as they could be, we compared the collected 
results of the same localizations and the same protocols from various clinics. The 
common significant difference from the databases can be accepted as evidence.  
 In the case of long-survivals, we have to consider, that oncothermia is taken only in a 
small fraction of the overall survival. The patients are treated by oncothermia in their 
definite late stages, after prognosis “no curative help” by continuing the gold-standards 
alone. In consequence, the long overall survival generally is not the result of the 
oncothermia, but the selection of the patients in their end. Oncothermia effect in these 
cases can be negligible, irrespective of its real efficacy. The chance to measure the 
efficacy is the first year survival rate (%), when the patients with the most aggressive 
kind of the given cancer do not survive the following year after the diagnosis. If they 
start the oncothermia in the first year, the survival-rate result can be an objective sign of 
the efficacy.  
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 Special cases are treated on Intend-to-Treat population. This makes the patient selection 
not objective enough, but the dominantly metastatic patient’s spectrum compensates for 
this lack of selection. In this case, we have an automatic selection of advanced (many 
times terminal) cases.  
  The generally low quality of life (QoL) in combination of supportive therapies weaken 
the measurability of oncothermia alone. However, due to the fact that oncothermia is 
not proposed as monotherapy, the combination objectively measures the benefit, if the 
supportive therapies alone would not be successful at all.  
 The patients are treated with oncothermia in their very advanced, metastatic states. The 
local oncothermia treatment, of course, concentrates on definite localizations, (primary 
or metastatic) which again lowers the full measurability of the oncothermia in the 
development of the cancer. This is the main reason why oncothermia measures first of 
all the overall survival rates, which are good objective parameters of the treatment 
efficacy in general.  
 The quality of life (QoL) of the patients is an important characteristic of such a method as 
oncothermia. In a generally controlled and randomized study a trial effect exists [356], 
which is not the case in oncothermia applications. However, it could be negative outcome, 
that in a strict competitive market the opinions are not independent and objective [357] 
and of course the conflict of interest could make considerable bias [358], [359].  
On the above bias structure the characteristics of the clinical studies could be described as – 
Single arm, open label, observational for intention-to-treat (ITT) population, dominantly for 
the patients in late/advanced stages, where the conventional methods have failed. Mostly 
the survival rate was the studied endpoint. The inclusion criteria were the inoperable and in 
progression after chemo- and/or radio-therapy. Exclusions were only the well-known, above 
described contraindications of oncothermia. 
The oncothermia challenge is its use when the conventional treatments are unsuccessful. In 
consequence, its effect could be active only in a small (last) fraction of the overall survival. 
When patients have long overall survival by the conventional treatments alone, oncothermia 
is applied only in the last stage of the disease so objectively the life-elongation by 
oncothermia can not be observed.   
To make an objective evaluation, we have special considerations how to get the evidences 
from the available information pool and find the objective evidences. It is a complex 
challenge, having four basic approaches. These methods highlight the objective information 
and their parallel results make the obtained data evidence-based. The five legs are: 
1. Fast course case comparison. Use the survival of the rapid, fast course cases (most 
advanced, drastically quickly developing cases) in comparison with large databases. 
(Only the survival is considered as relevant parameter, the clinical outcomes 
(responses) are not studied as evidences.)  
2. Comparison of clinics. Compare the obtained data of the independent clinics, using the 
same protocol for the same cohort.  
3. Quality of life comparison. Collect the data about the quality of life and the adverse 
effects limiting the application of oncothermia.  
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4. Create a quasi-control arm. Patients having no benefit from oncothermia could form a 
quasi-arm for control. The “no benefit” category could be defined when the patient 
survival is short from the time of the first oncothermia treatment.  
5. Parametric evaluation. Use the available latest statistical knowledge to find the relevant 
parameters of the survivals and use the best fit of the parametric distribution for 
evaluation.  
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Brain gliomas 27 86.2 23.6 43 66.2 18.2 [360], 
[361] 
Brain-glioma study Phase II, Retrospective 140 71.7     [362], 
[363] 
 
Astrocytoma  40  25.8 80 40.2 20.2 
Glioblastoma 92  16 73 21.9 13.1 
Diffuse astrocytoma 8  52.9    
Glioma (WHO IV) Study, Phase II, 
prospective, two arms
45   15       [160], 
[364] 
Passive arm 36 40 11    
Active arm 9 65 14.5 43 66.2 18.2 
Recurrent glioblastoma study, 
Phase II, retrospective, 
19 68.0 21.8 59 32.6 12.4 [365] 
Glioma study, Phase II, retrospective 36 60.0         [366] 
Astrocytoma 9  106    
Glioblastoma 27  20    
Glioma study, Phase II, retrospective 179           [367] 
 
 
Astrocytoma 53 100 103    
Glioblastoma 126 76 16    
Advanced, relapsed brain gliomas, Phase 
II, retrospective 
12   10 25     [368] 
 
Brain glioma WHO III-IV, Phase I, safety 
prospective 
15           [369], 
[370], 
[371], 
[372] 
Head and neck study, Phase II.  
retrospective 
64 92.2 26.1       [160], 
[373] 
Bone-metastases, monotherapy, 
Phase II, retrospective 
6 100 40.1       [160], 
[373] 
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Refractory bone-metastases study, Phase 
II, retrospective 
11     90.9     [374] 
 
Breast cancers 103 97.1 52.1 45 274.8 10.9 [160] , 
[373] 
Colorectal cancer () 218 84.9 28.5      [160] , 
[373] 
 
 
 
Sigma  12   34.1   
Rectum  92     57.1  58  21 
Colon  114     44.2 109.8 23.2 
Colon cancer study, , Phase II, 
prospective, three arms, randomized  
154          [375] 
[376] 
 
 
Clifford TCM  53   75   
Monotherapy  50   81   
Combined therapy  51   91   
Esophagus study, Phase II, retrospective 12 41.7 28.5 35 29.4 8.5 [160], 
[377] 
Rectum cancer study, 
Inoperable→operable, Phase II, 
retrospective 
7     71     [378] 
 
Kidney cancer study, Phase II, 
retrospective 
39 84.6 35.9 48 78.4 33.7 [160], 
[373] 
Liver metastases from various origin, 
Phase II, retrospective  
25   20.5       [379] 
 
Liver metastases from various origin,  
Comparative study, Phase II, retrospective
28           [374] 
 
 
 
With radiotherapy 16   81   
With chemotherapy 8   38   
Monotherapy 4   25   
Liver metastasis form colorectal origin, 
Phase II, retrospective
80 86.0 24.1       [380] 
 
 
 
Passive arm  53 11    
Active arm 80 91 24.1    
With chemotherapy 30 80 21.5    
Monotherapy 50 92 24.4    
Liver metastasis form colorectal origin, 
Phase II, retrospective 
15    23 80     [381] 
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Liver metastasis form colorectal origin, 
Phase II, retrospective 
22   28       [382] 
Rectal cancer, non-operable, , Phase II, 
retrospective 
65      96     [383] 
 
Liver metastasis 29   86   
Metastatic brain tumors study, Phase II, 
retrospective 
15 90.0 46.2 73 48.2 16.1 [368] 
Non-small cell lung cancer meta-analysis 311       [384] 
 
 
 
Passive arm 53 26.5 14    
Active arm 258 67.0 15.8 21 53.4 18.1 
Non-advanced (WHO<III) 77  11 17   
Advanced (WHO≥III) 140  14.7 88   
Lung carcinoma study, Phase II, 
retrospective 
61 67.2 16.4    [385], 
[160] 
Pancreas tumor study, Phase II, 
retrospective 
26 46.2 11.6    [386] 
Liver metastasis form colorectal origin, 
Phase II, retrospective 
30   22       [387] 
 
Pancreas tumor study, Phase II, 
retrospective 
107         [385] 
 
 Passive arm 34  6.5    
Active arm 73 52.1 9.93 58 25.5 8.4 
Pancreas tumor study, Phase II, 
retrospective 
30 31.0   41 34.4 5.6 [388], 
[389] 
Pancreas tumor study, Phase II, 
retrospective 
42 52.4 12.3       [390] 
 
Pancreas tumor study, Phase II, 
retrospective 
13 40.0 11.9       [391] 
Pelvic gynecological cancer studies, Phase 
II, retrospective 
74      [392] 
 
 Cervix 38 86.8 27.6 25 63.5 20.9 
Ovary 27 100 37.8 67 132.7 19.4 
Uterus 9 100 61.5 62 68.5 32.0 
Prostate cancer study, Phase II, 
retrospective 
18 88.9 38.8 72 53.4 7.6 [377] 
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Esophagus study, Phase II, retrospective 7    6.8 100     [378] 
Soft tissue sarcoma study, Phase II, 
retrospective 
16 100 35.9 31 115.3 31.3 [160] 
Stomach cancer study, Phase II, 
retrospective  
68 58.9 14.4       [160] 
Urinary bladder cancer study, Phase II, 
retrospective 
18 85.0 36.5 73 42.0 22.6 [160] 
Table 1. Summary of the studies made by oncothermia treatment 
We show, as spectacular examples, two important categories in comparison with the 
literature: the sensitive extra-cranial (non-invasive) brain glioma treatments and the 
treatments of the aggressive pancreas tumors.  
4.4.1. Comparison of brain studies 
Some more open-label, single arm, monocentric, retrospective and intention-to-treat frame 
oncothermia studies were published at professional conferences, [393], [394], [395], [396], 
[397] as well.  
The comparison of the median survivals for anaplastic astrocytoma and for glioblastoma 
multiform obtained by different clinics shows good correlations. Their glioblastoma 
multiform (WHO IV) results are ranging from 14-25.2 months median survival (weighted 
mean is 19.1 months), while the literature ([352], [398], [399], [400]), uses only 10.5 months 
weighted mean.  
According to the RTOG classifications [401], we divided the patients into two groups: age 
under- and over-50 years. By this division in cases of glioblastoma oncothermia has 14.4 and 
19 months for over and under 50 years of ages, [397]; while RTOG has 9.7 and 13.7 months, 
[401]; respectively. The method shows successful applications in pediatric cases as well, [402].  
The results are pretty coherently above the statistical values of the large databases SEER [352] 
and the gold-standard radiotherapy (RT) and RT+PCV [398]. The results of oncothermia show 
advantages in comparison with the publications on Temozolomide [399], [400], too.  
The first-year survival rates compared to SEER [352] and EUROCARE [353] databases as 
well as to the recent chemotherapy of Temozolomide also show significant advantages 
(more than 25% increase) of oncothermia. 
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No serious side effects were observed [403]. Patients tolerated the treatments well during 
the whole treatment period. Most of the patients were well relaxed, some even fell asleep 
during the treatment. Patients reported better quality of life, but this information was not 
objectively measured.   
The results well indicate the feasibility and the benefit of the oncothermia showing a valid 
treatment potential and safe application. Oncothermia is a potential way to escape from the 
present impasse situation and could treat brain gliomas successfully. Question of Editorial 
of JAMA “Where to go from here?” [404] could be answered with the help of the 
oncothermia way.  
4.4.2. Comparison of pancreas efficacy studies I. & II 
For clear evidence of the results, let us compare the first year survivals and the median 
survivals obtained in various clinics in comparison to the historical control and the large 
databases. The weighted average of five clinics of the first year survival percentages and the 
median survival times are 47.5 % and 12.4 months for oncothermia, while the references 
(large databases SEER and EUROCARE) show 15.6 % and 7.3 months, respectively. 
5. Future – To join or not to join?  
Oncothermia formulated a new paradigm: [72], and made it clear “What is against the 
acceptance of hyperthermia?” [83]. The problem is the misleading aim of getting 
uncontrollable temperature as dose and ignoring the physiological reaction of the patients.  
The philosophy of oncothermia simply follows the line of Hypocrates: “Nil Nocere” (“Do 
not harm”). Of course this has to be understood as “be natural as much as possible”. 
Oncothermia supports the natural processes of living organisms, applying the normal 
physiological and biophysical reactions of the body, using these to fight against the 
malignancy on standard way. The basic problem of the malignancy is that the immune 
system and all the protective mechanisms of the organism do not fight against this lesion, do 
not recognize the danger, they handle it as a normal tissue, supply and try to solve the 
irregularities, if it was  a wound. By the appropriate selective mechanism, oncothermia is 
able to “discover” these irregularities, showing their differences from the normal tissue and 
activate the standard protective, defense mechanisms in the body to fight.  
5.1. Natural treatment paradigm 
The natural therapy must help the body’s internal corrective actions to reestablish the 
healthy state. In normal healthy state the body is in homeostasis, which is controlled by 
numerous negative feedback loops, making the actual state definitely “constant” despite its 
energetically open status, (see Figure 45.). The disease breaks up the relative equilibrium, 
and the body tries to reestablish the homeostasis. For this enhanced negative feedback 
control is enforced (see Figure 46.). Recognizing the disease, we act with our medical 
knowledge, and in many cases, we work against the natural homeostasis, the constrained 
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action induces new homeostatic negative feedback. The body starts to fight against our 
constraints together with the disease (see Figure 47.). This controversial situation happens 
with classical hyperthermia, when the constrained massive temperature change is 
physiologically down-regulated (or at least the physiology works against it by the systemic 
[like blood-flow] and local [like HSP] reactions). Oncothermia disclaims the old approach, 
introducing a new paradigm: with the application of micro-heating, it induces considerably 
less physiological feedback to work against the action, and with the application of the 
electric field it uses such effect, for which the body has no physiological answer. With this 
new paradigm, oncothermia helps the natural feedback mechanisms to reestablish the 
healthy state (see Figure 48.).  
 
 
Figure 45. The natural healthy state is stabilized by the negative feedback loops of physiology 
 
 
Figure 46. The disease breaks the homeostasis, so the physiology tries to compensate and correct the 
damage 
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Figure 47. The classical hyperthermia introduces a new constrained effect which induces even more 
physiological feedback, forcing the body for the “double front” fight 
 
Figure 48. Oncothermia acts differently. It helps the natural feedback loops for natural corrections 
Oncothermia blocks the physiological positive feedbacks, reestablishes the homeostasis to 
the level, which the actual conditions allow. The blocks are effective:   
 The growth of cancer itself has a positive feedback loop. The rate of proliferation 
depends on the actual mass of the tumor, so the tumor mass gradually grows. Selective 
blocking of malignant autonomy could eliminate the positive feedback loop of 
malignancy.  
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 The lowering of the pH of the tumor is also a positive feedback loop. By the blocking of 
the high metabolic rate, the pH-loop is eliminated as well.  
 The injury current loop also has positive feedback. This is broken by the flow of the 
electric current density.  
 The neoangiogenesis is also a positive feedback, supporting the tumor by its accelerated 
nutrition demand. The electric current prefers the new vessels for conduction, blocking 
their actions.  
 The growing temperature decreases the impedance (increases the conductance by the 
mobility of the ions) in the tumor. This positive feedback loop is used till the 
temperature does not increase too much. The step-up heating uses this effect and 
controls this loop.  
 The growing temperature blocks the blood-flow in the tumor, which traps the heat in 
the center of the tumor. The heat-trap makes necrosis in the center of the tumor, which 
is anyway very acidic, and in most cases it is necrotized naturally. In artificial focusing, 
this necrotized volume remains the main target, however it does not need more energy. 
The real danger of the tumor is the vividly living outer “shell” which is responsible for 
metastases and for the volume-occupying rapid growth as well. The oncothermia 
current flows through this “shell” irrespective of how large the necrotic center is, and 
makes the oncothermia effective. It is shown, that after oncothermia the proliferation 
activity is drastically suppressed even in the possible remaining tumor tissue, which of 
course was massively targeted by the RF current.  
5.2. Epilogue 
Hyperthermia is an ancient treatment. It was the very first one in oncology, but it could not 
find its established place among the “gold standards” of the oncotherapies. The controversial 
results were originated from the paradigm to constrain the temperature growth in the process. 
The constrained forces made physiological contra-reactions keep the homeostasis, which 
unfortunately contains the malignant tissue as well. The actions have to be selective, and have 
to be gentle enough to work together with the natural processes, and not against them. 
Oncothermia selects the malignant cells and acts differently from the physiological 
homeostatic reactions (heat-flow on the membrane supported by the electric field effects). It 
is natural, it is not against the homeostasis and physiology does not work against the action. 
The main task is to direct the physiology in the standard way, and act on such normal line. 
The positive feedback loops (the avalanche effects), which may destroy the normal 
homeostatic equilibrium have to be stopped.  
Oncothermia follows the update demands of the modern oncology:  
 It is a personalized therapy,  
 It is non- toxic,  
 It elongates the survival time of the patients,  
 It completes the curative actions with increased quality of life 
 It has good cost/benefit ratio 
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The introduced new paradigm by oncothermia solved the classical challenges:  
 Challenge (1): “The biology is with us while the physics is against us” (Overgard J., 
[405]). 
- Oncothermia solution: “The biophysics is with us” 
 Challenge (2): “The biology and the physics are with us while the physiology is against 
us” (Osinsky S., [88]). 
- Oncothermia solution: “The fractal physiology is with us”  
 Challenge (3): “Reference point is needed!” (Fatehi D. van der Zee J., et. al. [406]).  
- Oncothermia solution: “Back to the gold standards, use the energy instead of 
temperature” 
The task for the future is challenging, and we are expecting professionals to repeat our 
results and come with us to fight in the war against cancer [407].  
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